



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 48/00, 38/18	A1	(11) International Publication Number: WO 97/12635 (43) International Publication Date: 10 April 1997 (10.04.97)
(21) International Application Number: PCT/US96/15824 (22) International Filing Date: 2 October 1996 (02.10.96) (30) Priority Data: 08/537,338 2 October 1995 (02.10.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/537,338 (CIP) Filed on 2 October 1995 (02.10.95) (71) Applicant (for all designated States except US): CYTOTHER- APEUTICS, INC. [US/US]; 2 Richmond Square, Provi- dence, RI 02906 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): AEBISCHER, Patrick [CH/CH]; Route de Lausanne 163A, CH-1096 Villette (CH). BAETGE, E., Edward [US/US]; 73 Sowams Road, Barring- ton, RI 02806 (US). HAMMANG, Joseph, P. [US/US]; 3 Prospect Street, Barrington, RI 02806 (US). (74) Agents: MASSARO, Jane, A. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020-1104 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>	
(54) Title: METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS		
(57) Abstract <p>A method for treating amyotrophic lateral sclerosis in a patient suffering therefrom comprising administering, directly into the central nervous system of said patient, ciliary neurotrophic factor, in a dose sufficient to maintain a measurable level of ciliary neurotrophic factor up to 1000 ng/ml in the cerebrospinal fluid, preferably 0.1-100 ng/ml, or a dose of hCNTF between 1-10,000 ng/day, preferably 250-1000 ng/day.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS

TECHNICAL FIELD OF THE INVENTION

This invention relates to treatment of amyotrophic lateral sclerosis (ALS) by delivery of hCNTF directly into the central nervous system, preferably
5 using encapsulated hCNTF-secreting cells.

BACKGROUND OF THE INVENTION

Amyotrophic lateral sclerosis, also known as maladie de Charcot, Lou Gehrig's disease or motor neuron disease, hereafter "ALS", is a progressive fatal disease of the voluntary motor system resulting in death within 2 to 5 years of
10 onset. The cause of the disease is unknown and no effective therapy has yet been devised. Quantitative measurement of the isometric force generated by a set of muscles allows progression of the disease to be monitored.

ALS is a common disease, with an annual incidence rate of 0.4 to 1.76 per 100,000 population (approximately 1,000-4,300 annually in the U.S.).
15 Most patients are more than 50 years old at the onset of symptoms and the incidence increases with each decade of life. ALS occurs in a random pattern throughout the world; it is estimated that in about 5% of cases ALS is familial, being inherited as an autosomal dominant trait.

The pathology of ALS is characterized by vacuolization and
20 neurofilament accumulation in the perikaryon and proximal axonal compartment. The process of neuronal injury appears to be implicated with oxidative stress and excitotoxic injury (Brown RHJ, "Amyotrophic Lateral Sclerosis: recent insight from genetic and transgenic mice," Cell 80; pp. 687- 692, (1995); Martinou J, Martinou

- 2 -

I, Kato AC, "Cholinergic differentiation factor promotes survival of isolated rat embryonic motoneurons *in vitro*," Neuron 8; pp. 737-744, (1992). The cause of death is usually respiratory failure.

There are currently no approved drugs for the treatment of ALS.

- 5 On September 19, 1995 an advisory panel to the Food and Drug Administration recommended approval of riluzole. Riluzole does not slow muscle deterioration or alleviate a patient's symptoms. Studies indicate it may extend lifespan for a short period (up to 3 months). The list of drug or treatment failures in ALS clinical trials is long, and includes Lamotrigine, n-acetyl cysteine, threonine, TRH,
- 10 dextromethorphan, gangliosides (Cronassail), rhGH, two CNTFs, a number of immunosuppressive trials with plasma exchange, intrathecal steroids, azathioprine, cyclophosphamide, cyclosporine and total lymphoid irradiation.

There have been a number of human clinical trials exploring treatments for ALS. Completed trials include: Genentech's rhGH (recombinant

15 human growth hormone), Regeneron's rhCNTF (ciliary neurotrophic factor), Syntex/Synergen's rhCNTF, RPR's two riluzole trials, Cephalon/Chiron's rhIGF-1 (Myotrophin) trial and a TRH (throtropin-releasing hormone) trial.

Human ciliary neurotrophic factor (hCNTF) is a potent neurotrophic factor which may have utility for the treatment of ALS.

- 20 Human CNTF and the gene encoding human CNTF are described in detail in United States patent numbers 4,997,929, 5,141,856 and co-pending United States patent application serial number 07/857,544 filed March 24, 1992. Each of those documents are specifically incorporated herein by this reference. Although the biological role of CNTF has not been conclusively established, CNTF appears to
- 25 be released upon injury to the nervous system and may limit the extent of injury or neuronal damage.

In the present invention, methods provided for the treatment of ALS by the administration of ciliary neurotrophic factor (CNTF) or other suitable molecule directly to the central nervous system ("CNS").

- 30 Systemic delivery of CNTF in humans has been frustrated by peripheral side effects, the molecule's short half life, and its inability to cross the

- 3 -

blood-brain barrier. In clinical studies, systemic administration of CNTF for the treatment of ALS resulted in the development of significant side effects (weight loss, CNTF antibody formation, fever, etc.), causing a halt to its development as a systemically administered drug for this treatment. In fact, the only two human
5 clinical trials using CNTF (Regeneron and Syntex/Synergen) for ALS therapy both had to be stopped because of side effects.

Doses of drug in the Regeneron trial were about 975 and 1950 µg/person, three times per week, assuming an average weight of 65 kg/person. This weekly dose was about 1.3-25 times as high as in the Syntex/Synergen Phase
10 III trial. No CNTF was detected in the cerebrospinal fluid (CSF) in either the Regeneron or Syntex/Synergen trial.

Regeneron's rhCNTF (ciliary neurotrophic factor) was shown to be toxic in a large Phase III (730 patients) ALS clinical trial. At one and two months, there was a significant loss in muscle strength, significant weight loss and a loss of
15 pulmonary function (Forced vital capacity or FVC). After two months, however, the differences diminished between drug and placebo, and by the end of the nine-month trial, there were no differences in the slope of isometric muscle strength loss (primary endpoint), FVC slope or weight loss slope. Throughout the trial, there was never a difference in survival. It is interesting to note that at two months,
20 the number of neutralizing antibodies (antibodies against rhCNTF) significantly increased, possibly indicating that further damage from CNTF was prevented by these antibodies inactivating CNTF.

There were numerous side effects that were statistically higher in the drug-treated group than the placebo group in Regeneron's trial: cough, asthenia
25 (weakness), nausea, anorexia, mouth ulcers (aphthous stomatitis), fever, injection site inflammation, weight loss, diarrhea, insomnia and vomiting. The cough side effect in this trial was unblinding (at least to some treating physicians). For the first two months in drug-treated patients, it was a severe/life-threatening cough in 15%-18% of patients and a mild/moderate cough in 75%-85% of patients (only
30 10%-15% of placebo patients had a mild/moderate cough during the first two months). At three months of treatment, the cough side effect began to decrease.

- 4 -

Injection site inflammation also was probably unblinding; about 30% of drug-treated patients had this side effect.

Syntex/Synergen, WO 94/17818 discloses methods for treating amyotrophic lateral sclerosis with CNTF. That application specifies that the preferred mode of administration is subcutaneous or intravenous delivery at 0.5-50
5 $\mu\text{g}/\text{kg}/\text{day}$ dosage. In addition, the application notes that dosages of CNTF given to patients in clinical trials were roughly 2, 5, 10 and 20 $\mu\text{g}/\text{kg}/\text{day}$. Another report suggests that daily doses of CNTF in the Syntex/Synergen trial were about 32, 130 and 325 μg per person. Smith Barney Report July 7, 1995, at p. 4. This would
10 correlate to an actual dose of 0.5, 2 and 5 $\mu\text{g}/\text{kg}/\text{day}$ (assuming an average weight of 65 kg/person).

Syntex/Synergen's rhCNTF Phase III trial (570 patients) was also shown to be toxic. The most disturbing result of this study was that one month after completing the six-month trial (during the washout period), a statistically
15 significant number of patients who had been on the high-dose drug arm died (16% versus 7% placebo). An increase in toxicity and death rate was observed with the high dose, but nobody knows why.

Because growth factors such as CNTF do not cross the blood brain barrier well, and because they are readily degraded in the blood stream, delivering
20 drugs to their appropriate site of action without adverse side effects is a major challenge as shown by the Regeneron and Syntex/Synergen trials.

The gene therapy approach described here is expected to mitigate such difficulties by local intrathecal delivery of a much lower dose of continuously-produced hCNTF from a retrievable implant.

25 SUMMARY OF THE INVENTION

This invention provides novel methods and devices for treating ALS by delivery of a continuously-produced source of human ciliary neurotrophic factor (hCNTF). In one embodiment, a tethered device, containing about $1-3 \times 10^6$ genetically modified cells surrounded by a semipermeable membrane, is implanted
30 intrathecally; it provides for slow, continuous release of hCNTF at a rate of 1-1500

- 5 -

ng/day, preferably 250-1000 ng/day. The dosage should be sufficient to produce a measurable level of CNTF in the cerebrospinal fluid ("CSF"). Higher output is also contemplated, provided that delivery is to the central nervous system (CNS), and not through a route of administration that leads to the above-mentioned side effects.

5 According to one embodiment, CNTF (or other suitable molecule) is delivered at a dosage sufficient to maintain a measurable concentration of up to 1000 ng/ml in the CSF, preferably between 0.01 ng/ml - 1000 ng/ml in the CSF, most preferably between 0.1-100 ng/ml in the CSF. The semipermeable membrane prevents immunologic rejection of the cells and
10 interposes a physical, virally impermeable barrier between cells and host. Moreover, the device and the cells it contains may be retrieved from the patient.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1: CNTF levels measured in the CSF at 2.5 months, 3 months and 7 weeks in human patients 1-5.

15 Fig. 2: C reactive protein and fibrinogen measurements.

Fig. 3: Neutrophils and lymphocytes did not vary over the three plus month period under study.

Fig. 4: Total wbc and ESR remained within the normal range throughout the study.

20 Fig. 5: Weight was constant throughout the study.

Fig. 6: The three reimplanted patients were rechecked for CSF levels of CNTF. Patients 1 and 3 had detectable levels, patient 2 did not

Fig. 7: Norris scores on patient 1 (Panel A), patient 2 (Panel B), patient 3 (Panel C), patient 4 (Panel D), and patient 5 (Panel E).

25 Fig. 8: Plasmid map of RP 3224E2, the pNUT vector containing the hCNTF gene and containing the TK gene at the NotI site.

Figure 9: pNUT-hCNTF-NT expression vector. The hCNTF gene was subcloned into the DHFR-based pNUT expression vector. MT-1 promoter: mouse metallothionein I promoter; Ig signal sequence: mouse immunoglobulin
30 signal sequence; hGH-3'UT: 3' untranslated human growth hormone region

- 6 -

containing the polyadenylation signal; HSV-tk gene: herpes simplex virus thymidine kinase gene; NEO^R gene: neomycin resistance gene; SV40 promoter: simian virus 40 promoter.

DETAILED DESCRIPTION OF THE INVENTION

5 This invention relates to delivery of CNTF directly into the CNS without having to cross the blood brain barrier. The dosage provided is sufficient to achieve a measurable level of up to 1000 ng/ml in the cerebrospinal fluid (CSF), preferably between 0.01-1000 ng/ml in the CSF, most preferably between 0.1-100 ng/ml in the CSF. In one embodiment, living cells are encapsulated in one or more
10 semipermeable polymer capsules and surgically inserted (under local anesthesia) into the CNS.

 In one embodiment, this invention may be useful in the treatment of ALS. Sporadic ALS is the most common form of the disease and there are several important subtypes. Classical ALS, the most common subtype, is distinguished by
15 both upper and lower motor neuron degeneration. Progressive bulbar palsy (PBP) affects approximately 25% of the ALS population and in early stages involves atrophy of muscles innervated by neurons in the lower cranial brainstem, thereby affecting speech and mastication in its early stages. Symptoms of progressive muscular atrophy (PMA) characterizes 8-10% of the ALS population, and involves
20 initial degeneration of the lower motor neurons and lower brainstem. Finally, primary lateral sclerosis (PLS), the rarest of the subfamilies, targets the upper motor neurons. Other types of the disease include familial ALS, Western Pacific ALS, Juvenile ALS and ALS-like diseases with definable causes (e.g., Post-polio syndrome, heavy metal intoxication, etc.).

25 This technique provides several advantages over other delivery routes:

(1) Drug can be delivered to the CNS directly, which will reduce unwanted peripheral side effects;

(2) Very small doses of drug (nanogram or low microgram quantities rather than milligrams) can be delivered compared with subcutaneous injections, also leading to fewer side effects;

(3) If cells are viable for long periods of time (such as six months),
5 patients will be inconvenienced only twice a year instead of three times weekly or every day with subcutaneous injections (oral pills become inconvenient later in disease progression, when swallowing becomes difficult and is also technically impractical due to breakdown of the protein);

(4) Since viable cells continuously produce newly synthesized product,
10 these cells should have advantages over pump delivery of drug stores, where drug is continuously degraded but not continuously replenished.

Due to its instability, CNTF cannot be easily administered continuously -- potentially the best mode of therapy. When administered outside of the CNS, via pump, over 90% of CNTF activity is lost within 12 hours. It is also
15 hypothesized that sustained delivery of CNTF may prevent the down-regulation of the CNTF receptor that typically occurs with repeated bolus administrations.

The shorter half-life of CNTF in the blood stream and the requirement for retrograde transport suggests that motoneurons will have a diminished exposure to CNTF when administered by subcutaneous injection.

20 Experiments in sheep have shown that CNTF is toxic when given in a bolus injection intrathecally (personal communication from Dr. M. Sendtner). Large doses of CNTF can therefore not be delivered intrathecally, although intrathecal delivery may be more efficacious since it can act directly on the cell body receptors of the lower motoneurons (spinal motoneurons) and potentially on the
25 upper motoneurons (cortical motoneurons; Betz cells) as well. The latter are inaccessible by systemic delivery since the blood brain barrier inhibits the diffusion of CNTF directly into the central nervous system.

Spinal, but not cortical motoneurons have access to CNTF administered systemically via retrograde transport from the muscle end plates.
30 Because of the inherent instability of CNTF (Kato AC, Lindsay RM, "Overlapping and additive effects of neurotrophins and CNTF on cultured human spinal cord

neurons," Exp Neurol, Vol. 130, p. 96 (1994)), continuous intrathecal delivery by means of pumps is of low feasibility.

Delivery of CNTF through gene therapy (i.e., via transplantation of polymer encapsulated cells genetically engineered to release CNTF) circumvents the majority of these problems.

The preferred CNTFs used in the present invention are the naturally-occurring human proteins, such as those described in U.S. patents 5,011,914; 5,141,856; and 4,997,929 all of which are incorporated herein by reference. Modified, truncated and mutein forms of CNTF are well known. See, e.g., WO 94/09134 and WO 93/10233. All of these forms of CNTF are contemplated by this invention. Each of these patents and patent applications are specifically incorporated herein by reference. Further, active fragments of CNTF (i.e., those fragments of CNTF having biological activity sufficient to achieve a therapeutic effect) are contemplated. The present invention also encompasses both microbially produced and mammalian cell produced forms of CNTF. Also contemplated are CNTF molecules modified by attachment of one or more polyethylene glycol (PEG) or other repeating polymeric moieties. Combinations of these proteins and polycistronic versions thereof are also contemplated.

The nucleic acid sequences of the genes encoding human and animal CNTFs and the amino acid sequences of such proteins are known. See, e.g., U.S. patent numbers 4,997,929 and 5,141,856, incorporated herein by reference.

In a preferred embodiment, full length recombinant human CNTF (rhCNTF) is used.

A gene of interest (i.e., a gene that encodes a suitable biologically active molecule, e.g., CNTF) can be inserted into a cloning site of a suitable expression vector by using standard techniques. It will be appreciated that more than one gene may be inserted into a suitable expression vector. These techniques are well known to those skilled in the art.

The expression vector containing the gene of interest may then be used to transfect the desired cell line. Standard transfection techniques such as calcium phosphate co-precipitation, DEAE-dextran transfection or electroporation

may be utilized. Commercially available mammalian transfection kits may be purchased from e.g., Stratagene.

A wide variety of host/expression vector combinations may be used to express the gene encoding CNTF, or other biologically active molecule of
5 interest.

Suitable promoters include, for example, the early and late promoters of SV40 or adenovirus and other known non-retroviral promoters capable of controlling gene expression.

Useful expression vectors, for example, may consist of segments of
10 chromosomal, non-chromosomal and synthetic DNA sequences, such as various known derivatives of SV40 and known bacterial plasmids, e.g., pUC, pBlueScript™ plasmids from *E. coli* including pBR322, pCR1, pMB9, pUC, pBlueScript™ and their derivatives.

Expression vectors containing the geneticin (G418) or hygromycin
15 drug selection genes (Southern, P.J., *In Vitro*, 18, p. 315 (1981), Southern, P.J. and Berg, P., *J. Mol. Appl. Genet.*, 1, p. 327 (1982)) are also useful. These vectors can employ a variety of different enhancer/promoter regions to drive the expression of both a biologic gene of interest (e.g., NGF) and/or a gene conferring resistance to selection with toxin such as G418 or hygromycin B. The G418 resistance gene
20 codes for aminoglycoside phosphotransferase (APH) which enzymatically inactivates G418 (100-500 µg/l) added to the culture medium. Only those cells expressing the APH gene will survive drug selection usually resulting in the expression of the second biologic gene as well. The hygromycin B phosphotransferase (HBH) gene codes for an enzyme which specifically modifies
25 hygromycin toxin and inactivates it. Genes cotransfected with or contained on the same plasmid as the hygromycin B phosphotransferase gene will be preferentially expressed in the presence of hygromycin B at 50-200 µg/ml concentrations.

A variety of different mammalian promoters can be employed to direct the expression of the genes for G418 and hygromycin B and/or the biologic
30 gene of interest. These promoters include, but are not limited to, the promoters of hDBH (human dopamine beta hydroxylase) (Mercer et al., *Neuron*, 7, pp. 703-716,

- 10 -

(1991)), hTH (human tyrosine hydroxylase) (Kaneda, et al., Neuron, 6, pp. 583-594 (1991)), hPNMT (human phenylethanolamine N-methyltransferase) (Baetge et al., PNAS, 85, pp. 3648-3652 (1988)), mGFAP (mouse glial fibrillary acidic protein) (Besnard et al., J. Biol. Chem., 266, pp. 18877-18883 (1991)), myelin basic protein (MBP), mNF-L (mouse neurofilament-light subunit) (Nakahira et al., J. Biol. Chem., 265, pp. 19786-19791 (1990)), hP₀ (human P₀, the promoter for the gene encoding the major myelin glycoprotein in the peripheral nervous system) (Lemke et al., Neuron, 1, pp. 73-83 (1988)), mMT, rNSE (rat neuron-specific enolase) (Sakimura, et al., Gene, 60, pp. 103-113 (1987)), and the like.

10 Examples of expression vectors that can be employed are the commercially available pRC/CMV, pRC/RSV, and pCDNA1NEO (InVitrogen). The viral promoter regions directing the transcription of the drug selection and biologic genes of interest are replaced with one of the above promoter sequences that are not subject to the down regulation experienced by viral promoters within
15 the CNS. For example, the GFAP promoter would be employed for the transfection of astrocytes and astrocyte cell lines, the TH promoter would be used in PC12 cells, or the MBP promoter would be used in oligodendrocytes. In one embodiment, the pNUT expression vector is used. Baetge et al., PNAS, 83, pp. 5454-58 (1986). In addition, the pNUT expression vector can be modified such
20 that the DHFR coding sequence is replaced by the coding sequence for G418 or hygromycin drug resistance. The SV40 promoter within the pNUT expression vector can also be replaced with any suitable constitutively expressed mammalian promoter, such as those discussed above.

 In a preferred embodiment, the human CNTF gene was expressed
25 from the above mentioned dihydrofolate reductase (DHFR)-based selection vector designated pNUT, which contains the cDNA of the mutant DHFR and the entire pUC18 sequence including the polylinker (Aebischer, P., et al., "Transplantation in humans of encapsulated xenogeneic cells without immunosuppression: A preliminary report," Transplantation, 58, pp. 1275-1277 (1994)). The DHFR
30 transcription unit is driven by the SV40 promoter and fused at its 3' end with the

- 11 -

hepatitis B virus gene polyadenylation signal (approximately 200 bp 3' untranslated region) to ensure efficient polyadenylation and maturation signals.

The hCNTF gene was expressed behind the mouse metallothionein I promoter and utilizes the human growth hormone polyadenylation signal sequence for 3' processing. The pNUT vector containing the CNTF gene insert was named
5 RP3224D.

This invention also contemplates use of a "suicide" gene in the transformed cells. Most preferably, the cell carries the TK (thymidine kinase) gene as a safety measure, permitting the host cell to be killed *in vivo* by treatment with
10 ganciclovir.

Use of a "suicide" gene is known in the art. See, e.g., Anderson, published PCT application WO 93/10218; Hamre, published PCT application WO 93/02556. The recipient's own immune system provides a first level of protection from adverse reactions to the implanted cells. If encapsulated, the polymer capsule
15 itself may be immuno-isolatory. The presence of the TK gene (or other suicide gene) in the expression construct adds an additional level of safety to the recipient of the implanted cells.

In a further preferred embodiment, the Herpes Simplex Virus Thymidine kinase (HSV-TK) gene was inserted into the CNTF pNUT RP3224D
20 construction. This suicide gene was included to allow elimination of the transfected cells upon ganciclovir administration. The 1800 bp fragment was inserted into the NotI site of the pNUT vector, yielding RP 3224E2. Figure 8. A typical dosage of ganciclovir required to "kill" the cells is approximately 5 mg/kg.

One preferred cell chosen for the gene transfer technique are baby
25 hamster kidney (BHK) cells. Cell lines offer several advantages including unlimited availability, the possibility of rapid screening *in vitro* for the presence of pathogens from which cell banks are established, and the suitability for stable gene transfer using non-viral-based recombinant DNA techniques.

Both allogeneic and xenogeneic cells may be used. Use of a cell line
30 of xenogeneic origin provides an additional advantage since the transplanted cells will be rejected by the host immune system in the event of device breakage.

- 12 -

These cells are surrounded with a permselective membrane which permits the diffusion of small molecules such as nutrients and trophic factors into and out of the polymer envelope, while excluding larger molecules of the immune system (antibodies, complement, etc.).

5 While BHK cells are one preferred cell, a wide variety of cells may be used. These include well known, publicly available immortalized cell lines as well as dividing primary cell cultures. Examples of suitable publicly available cell lines include, chinese hamster ovary (CHO), mouse fibroblast (L-M), NIH Swiss mouse embryo (NIH/3T3), African green monkey cell lines (including COS-1,
10 COS-7, BSC-1, BSC-40, BMT-10 and Vero), rat adrenal pheochromocytoma (PC12 and PC12A), AT3, rat glial tumor (C6), astrocytes and other fibroblast cell lines. Primary cells that may be used include, EGF-responsive neurospheres, bFGF-responsive neural progenitor stem cells derived from the CNS of mammals (Richards et al., PNAS 89, pp. 8591-8595 (1992); Ray et al., PNAS 90, pp.
15 3602-3606 (1993)), primary fibroblasts, Schwann cells, astrocytes, β -TC cells, Hep-G2 cells, oligodendrocytes and their precursors, myoblasts (including C₂C₁₂ cells) and the like. In another embodiment, C₂C₁₂ cells are preferred.

The cell types that can be employed for encapsulated cell therapy within the scope of this invention include cells from allogeneic and xenogeneic
20 sources. One of the principal advantages of our encapsulated approach rests with the immunoisolatory properties of the membranes of this invention, and their ability to support cells that otherwise would not be appropriate for transplantation (i.e., non-human sources, immortalized and/or tumor cell lines).

A particular advantage to using xenogeneic over allogeneic cells is
25 that in the unlikely event of membrane failure, the xenogeneic cells are more likely to be targeted for destruction by the immune system when compared to allogeneic cells. Furthermore, xenogeneic sources are easy to obtain and their use precludes the necessity for the use of human tissue which is difficult to obtain and fraught with societal and ethical considerations. In addition, human tissue may contain
30 adventitious agents that are more readily transmitted to the transplantation recipient. Finally, use of xenogeneic tissue and cell lines for transplantation in

humans removes the risks associated with the handling and processing of human tissue.

Increased expression can be achieved by increasing or amplifying the copy number of the transgene encoding CNTF or other suitable biologically active molecule(s), using amplification methods well known in the art. Such amplification methods include, e.g., DHFR amplification (see, e.g., Kaufman et al., United States patent 4,470,461) or glutamine synthetase ("GS") amplification (see, e.g., United States patent 5,122,464, and European published application EP 338,841).

In one embodiment of this invention, rhCNTF is delivered intrathecally using encapsulated cells. Baby hamster kidney (BHK) cells are genetically engineered to stably express and release recombinant human CNTF into the central nervous system (CNS).

In a preferred embodiment, the CNTF-pNUT expression vector is transfected into baby hamster kidney (BHK) cells using a standard calcium phosphate transfection procedure and selected with increasing concentrations of methotrexate (1 to 200 μM) over 8 weeks to produce stable amplified cell lines. Following this selection, the engineered BHK cells were maintained *in vitro* in 50-200 μM methotrexate.

No loss of CNTF expression has been observed, in the absence of drug selection over three months in culture, when screened by Northern blot analysis, CNTF bioassay, or ELISA for CNTF (R&D Systems, Inc.).

In some instances, the genetically altered cells are autologous to the host and may not require encapsulation.

According to the methods of this invention, other molecules may be co-delivered to the CNS including neural growth factors, cytokines, hormones, and neurotransmitters (including peptide neurotransmitters). In particular, co-delivery of IGF-1, NGF, GDNF, BDNF, NT-3, NT-4/5, NT-6, CT-1, IFN- α and IFN- β are contemplated.

In one preferred embodiment, CNTF and GDNF are co-delivered. In a second preferred embodiment, CNTF and NT-4/5 are co-delivered. In a third

- 14 -

preferred embodiment, CNTF and BDNF are co-delivered. In a fourth preferred embodiment, CNTF and IGF-I are co-delivered.

In a fifth embodiment, there is co-delivery of CNTF, GDNF and NT-4/5. In a sixth embodiment, there is co-delivery of CNTF, BDNF and NT-4/5.

5 In a seventh embodiment, there is co-delivery of CNTF, BDNF and GDNF. It will be appreciated that any combination of the foregoing molecules may be co-delivered with CNTF.

The co-delivered molecules are delivered in a dose similar to that of CNTF (i.e., sufficient to achieve a measureable level up to 1000 ng/ml in the CSF,
10 preferably between 0.01 - 1000 ng/ml in the CSF, most preferably between 0.1 ng/ml and 100 ng/ml).

Co-delivery can be accomplished in a number of ways. Cells may be transfected with separate constructs containing the genes encoding the described molecules. Alternatively, cells may be transfected with a single construct containing
15 two or more genes.

Multiple gene expression from a single transcript is preferred over expression from multiple transcription units. One approach for achieving expression of multiple genes from a single eukaryotic transcript takes advantage of sequences in picorna viral mRNAs known as internal ribosome entry sites ("IRES").
20 These sites function to facilitate protein translation from sequences located downstream from the first AUG of the mRNA.

Macejak and Sarnow reported that the 5' untranslated sequence of the immunoglobulin heavy chain binding protein (BiP, also known as CRP 78, the glucose-regulated protein of molecular weight 78,000) mRNA can directly confer
25 internal ribosome binding to an mRNA in mammalian cells, in a 5'-cap independent manner, indicating that translation initiation by an internal ribosome binding mechanism is used by this cellular mRNA. Macejak, *Nature*, 353, pp. 90-94 (1991).

WO 94/24870 refers to use of more than two IRES for translation
30 initiation from a single transcript, as well as to use of multiple copies of the same IRES in a single construct.

- 15 -

Various modified IRES sequences are known. See, e.g., Mountford and Smith, Trends Genet., 11, pp. 179-84 (1995); Dirks et al., Gene, 128, pp. 247-49 (1993); Martinez-Salas et al., J. Virology, 67, pp. 3748-55 (1993) and Mountford et al., Proc. Natl. Acad. Sci. USA, 91, pp. 4303-07 (1994). Use of
5 these modified sequences is also contemplated in this invention.

Any suitable method known to one of ordinary skill in the art may also be used.

Also contemplated is encapsulation of two or more separately transfected cells or cell lines, each secreting one of the desired molecules.

10 Co-encapsulation of adrenal chromaffin cells is also contemplated. Chromaffin cells are known to secrete a number of potentially therapeutic molecules.

This invention also contemplates use of different cell types during the course of the treatment regime. For example, a patient may be implanted with a
15 capsule device containing a first cell type (e.g., hCNTF-secreting BHK cells). If after time, the patient develops an immune response to that cell type, the capsule can be retrieved, or explanted, and a second capsule can be implanted containing a second cell type (e.g., C₂C₁₂ cells). In this manner, continuous provision of the therapeutic molecule is possible, even if the patient develops an immune response to
20 one of the encapsulated cell types.

As will be appreciated, any of the foregoing cells may be used to deliver CNTF (and any other co-delivered molecules, as set forth above).

Encapsulation hinders elements of the immune system from entering the capsule, thereby protecting the encapsulated cells from immune destruction.
25 This technology increases the diversity of cell types that can be employed in therapy. The semipermeable nature of the capsule membrane also permits the molecule of interest to easily diffuse from the capsule into the surrounding host tissue. This technique prevents the inherent risk of tumor formation and allows the use of unmatched human or even animal tissue, without immunosuppression of the
30 recipient. Moreover, the implant may be retrieved if necessary or desired. It is both undesirable and expensive to maintain a patient in an immunosuppressed state for a

- 16 -

substantial period of time. Such retrievability may be essential in many clinical situations.

Numerous encapsulation devices are known, having various outer surface morphologies and other mechanical and structural characteristics. Capsules
5 have been categorized as Type 1 (T1), Type 2 (T2), type 1/2 (T1/2) or Type 4 (T4) depending on their outer surface morphology. Such membranes are described, e.g., in Lacy et al., "Maintenance Of Normoglycemia In Diabetic Mice By Subcutaneous Xenografts Of Encapsulated Islets", Science, 254, pp. 1782-84 (1991), Dionne et al., PCT/US92/03327 and Baetge, WO 95/05452.

10 As used herein "a biocompatible capsule" means that the capsule, upon implantation in a host mammal, does not elicit a detrimental host response sufficient to result in the rejection of the capsule or to render it inoperable, for example through degradation.

As used herein "an immunoisolatory capsule" means that the capsule
15 upon implantation into a mammalian host minimizes the deleterious effects of the host's immune system on the cells within its core.

A variety of biocompatible immunoisolatory capsules are suitable for delivery of molecules according to this invention. Such capsules will allow for the passage of metabolites, nutrients and therapeutic substances while minimizing the
20 detrimental effects of the host immune system. Preferably the capsule of this invention will be similar to those described in Aebischer et al., PCT publication WO 92/19195, incorporated herein by reference.

Useful biocompatible polymer capsules comprise (a) a core which contains a cell or cells, either suspended in a liquid medium or immobilized within a
25 hydrogel or extracellular matrix, and (b) a surrounding or peripheral region of permselective matrix or membrane (jacket) which does not contain isolated cells, which is biocompatible, and which is sufficient to protect isolated cells if present in the core from detrimental immunological attack.

The core of the polymer capsule is constructed to provide a suitable
30 local environment for the continued viability and function of the cells isolated therein.

- 17 -

Many transformed cells or cell lines are most advantageously isolated within a capsule having a liquid core. For example, cells can be isolated within a capsule whose core comprises a nutrient medium, optionally containing a liquid source of additional factors to sustain cell viability and function, such as fetal
5 bovine or equine serum.

Suitably, the core may be composed of a matrix formed by a hydrogel which stabilizes the position of the cells in cell clumps. The term "hydrogel" herein refers to a three dimensional network of cross-linked hydrophilic polymers. The network is in the form of a gel, substantially composed of water,
10 preferably but not limited to gels being greater than 90% water.

Compositions which form hydrogels fall into three classes. The first class carries a net negative charge (e.g., alginate). The second class carries a net positive charge (e.g., collagen and laminin). Examples of commercially available extracellular matrix components include Matrigel™ and Vitrogen™. Fibroblasts
15 generally survive well in a positively charged matrix and are thus suitably enclosed in extracellular-matrix type hydrogels. The third class is net neutral in charge (e.g., highly crosslinked polyethylene oxide, or polyvinylalcohol). Any suitable matrix or spacer may be employed within the core, including precipitated chitosan, synthetic polymers and polymer blends, microcarriers and the like, depending upon the
20 growth characteristics of the cells to be encapsulated.

Preferably, the capsules are immunoisolatory. To be immunoisolatory, the surrounding or peripheral region of the capsule should confer protection of the cells from the immune system of the host in whom the capsule is implanted, by preventing harmful substances of the host's body from entering the
25 core of the vehicle, and by providing a physical barrier sufficient to prevent detrimental immunological contact between the isolated cells and the host's immune system. The thickness of this physical barrier can vary, but it will always be sufficiently thick to prevent direct contact between the cells and/or substances on either side of the barrier. The thickness of this region generally ranges between 5
30 and 200 microns; thicknesses of 10 to 100 microns are preferred, and thickness of 20 to 75 microns are particularly preferred. Types of immunological attack which

- 18 -

can be prevented or minimized by the use of the instant vehicle include attack by macrophages, neutrophils, cellular immune responses (e.g. natural killer cells and antibody-dependent T cell-mediated cytotoxicity (ADCC), and humoral response (e.g., antibody-dependent, complement-mediated cytotoxicity).

5 Use of immunoisulatory capsules allows the implantation of xenogeneic cells or tissue, without a concomitant need to immunosuppress the recipient. Use of immunoisulatory capsules also allows use of unmatched cells (allografts). The type and vigor of an immune response to xenogeneic cells is expected to differ from the response encountered when syngeneic or allogeneic
10 tissue is implanted into a recipient. This response may proceed primarily by cell-mediated, or by complement-mediated attack; the determining parameters in a particular case may be poorly understood. However, the exclusion of IgG from the core of the vehicle is not the touchstone of immunoprotection, because in most cases IgG alone is insufficient to produce cytotoxicity of the target cells or tissues.
15 Using immunoisulatory macrocapsules, it is possible to deliver needed high molecular weight products or to provide metabolic functions pertaining to high molecular weight substances, provided that critical substances necessary to the mediation of immunological attack are excluded from the immunoisulatory capsule. These substances may comprise the complement attack complex component C3b, or
20 they may comprise phagocytic or cytotoxic cells; the instant immunoisulatory capsule provides a protective barrier between these harmful substances and the isolated cells. Thus, an immunoisulatory capsule can be used for the delivery even from xenogeneic cells, products having a wide range of molecular sizes. Accordingly, nominal molecular weight cutoff (MWCO) values up to 1000 - 2000
25 kD are contemplated. Preferably, the MWCO is between 50-700 kD. Most preferably, the MWCO is between 70-300 kD.

 Various polymers and polymer blends can be used to manufacture the capsule jacket, including polyacrylates (including acrylic copolymers), polyvinylidenes, polyvinyl chloride copolymers, polyurethanes, polystyrenes,
30 polyamides, cellulose acetates, cellulose nitrates, polysulfones (including polyether

- 19 -

sulfones), polyphosphazenes, polyacrylonitriles, poly(acrylonitrile/covinyl chloride), as well as derivatives, copolymers and mixtures thereof.

The capsule can be any configuration appropriate for maintaining biological activity and providing access for delivery of the product or function, including for example, cylindrical, rectangular, disk-shaped, patch-shaped, ovoid, 5 stellate, or spherical. Moreover, the capsule can be coiled or wrapped into a mesh-like or nested structure. If the capsule is to be retrieved after it is implanted, configurations which tend to lead to migration of the capsules from the site of implantation, such as spherical capsules small enough to travel in the recipient's 10 blood vessels, are not preferred. Certain shapes, such as rectangles, patches, disks, cylinders, and flat sheets offer greater structural integrity and are preferable where retrieval is desired.

In one preferred embodiment, the implantable capsule is of a sufficient size and durability for complete retrieval after implantation. Preferably 15 the device has a tether that aids in retrieval. Such tethers are well known in the art. Such macrocapsules have a core of a preferable minimum volume of about 1 to 10 μl and depending upon use are easily fabricated to have a volume in excess of 100 μl .

The preferred capsule will have an inner single ultrafiltration 20 membrane with a permselective pore-size permeability range of 60-98% BSA rejection coefficient and 50-90% ovalbumin rejection coefficient.

In a hollow fiber configuration, the fiber will have an inside diameter of less than 1500 microns, preferably less than 300-600 microns. In either geometry, the hydraulic permeability will be in the range of 1-100 25 $\text{mls}/\text{min}/\text{M}^2/\text{mmHg}$, preferably in the range of 25 to 70 $\text{mls}/\text{min}/\text{M}^2/\text{mmHg}$. The glucose mass transfer coefficient of the capsule, defined, measured and calculated as described by Dionne et al., ASAIO Abstracts, p. 99 (1993), and Colton et al., The Kidney, eds., Brenner BM and Rector FC, pp. 2425-89 (1981) will be greater than 10^{-6} cm/sec , preferably greater than 10^{-4} cm/sec .

30 T1 membranes may be formed by coextrusion of a polymer solution and coagulant solution through air before entering a quench bath. T2 membranes

- 20 -

may be formed by coextruding the polymer, and coagulation solutions into humidified air or a mist and then into a bath. T4 membranes may be formed by coextrusion of the polymer and coagulant solutions directly into a coagulant bath, so that formation of the permselective membrane occurs on both outer and inner
5 wall surfaces simultaneously. Methods of making biocompatible, immunoisulatory semipermeable hollow fiber membranes are disclosed in United States patents 5,284,761 and 5,158,881, herein incorporated by reference.

T1/2 membranes may be formed using similar methods used to form T2 membranes. However, the mist or humidity at the coextrusion port may be
10 controlled according to known methods to produce the desired outer surface morphology. Alternatively, the nozzle distance from a quench bath may be varied, according to routine methods. Further, if coextrusion is used to cast the membrane, the absolute and/or relative flow rates of polymer and coagulant may be adjusted to achieve the desired outer wall surface morphology. Finally, the polymer and
15 coagulant solution compositions and temperatures can be varied to achieve the desired outer surface wall morphology. See WO 95/0542.

Any suitable method of sealing the capsules may be used, including the employment of polymer adhesives and/or crimping, knotting and heat sealing. These sealing techniques are known in the art. In addition, any suitable "dry"
20 sealing method can also be used. In such methods, a substantially non-porous fitting is provided through which the cell-containing solution is introduced. Subsequent to filling, the capsule is sealed. Such a method is described in copending United States application Serial No. 08/082,407, herein incorporated by reference.

25 In a preferred embodiment, the capsule is formed from a polyether sulfone hollow fiber, such as those described in United States Patent Nos. 4,976,859 and 4,968,733, herein incorporated by reference. In other embodiments we contemplate using microcapsules for cellular delivery. See, e.g., United States patents 4,352,883; 4,353,888; and 5,084,350, herein incorporated by reference.
30 Likewise, we also contemplate polymer rods (e.g., EVA rods) for delivery of CNTF.

The methods and devices of this invention are intended for use in a mammalian host, recipient, patient, subject or individual, preferably a primate, most preferably a human.

A number of different implantation sites are contemplated for the devices and methods of this invention. These implantation sites include the central nervous system, including the brain, spinal cord, and aqueous and vitreous humors of the eye. Preferred sites in the brain include the striatum, the cerebral cortex, subthalamic nuclei and nucleus Basalis of Maynert. Other preferred sites are the cerebrospinal fluid, most preferably the subarachnoid space and the lateral
10 ventricles.

According to one embodiment of this invention, capsular delivery of CNTF, synthesized in vivo, to the brain ventricles, brain parenchyma, the intrathecal space or other suitable CNS location, ranging from 1-10,000 ng/day, preferably 1-1500 ng/day, most preferably 250-1000 ng/day, is desirable. The actual dosage
15 can be varied by any suitable method known in the art, including, e.g., by implanting a fewer or greater number of capsules. We prefer between one and ten capsules. The dosage should be sufficient to produce a measurable level of CNTF in the CSF. The cell loading density may also be varied over a wide range. If macrocapsules are used, preferably between 10^3 and 10^8 cells are encapsulated, most preferably 10^5 to
20 10^7 cells are encapsulated.

Also according to this invention, CNTF (or other suitable molecule) is delivered at a dosage sufficient to maintain a measurable concentration up to 1000 ng/ml in the CSF, preferably between 0.01 ng/ml - 1000 ng/ml in the CSF, most preferably 0.1-100 ng/ml in the CSF.

25

EXAMPLES

We constructed a BHK cell line secreting rhCNTF. The cell line was tested in various in vitro and in vivo models. The cell line was further tested for safety in case of inadvertent release in the patient. With the safety results in hand, a pilot human clinical trial was initiated using encapsulated cells implanted in the
30 intrathecal space of 10 human patients.

- 22 -

The safety of encapsulated xenogeneic transfected cells is believed to be adequate for transplantation in humans for the following reasons:

- 1) the non-viral based vector is stably integrated into the cells, thus avoiding all independent replication events and possible transmission of the vector;
- 5 2) the semipermeable membrane surrounding the transplanted cells prevents any genetic exchange between the transfected cells and the human host cells;
- 3) in case of capsule breakage, the cells are rejected by the host immune system;
- 10 4) the expression vector constitutively produces thymidine kinase (HSV-tk), providing an additional means of eliminating the BHK cells in case of capsule breakage through the administration of ganciclovir;
- 5) no adverse inflammatory reaction against a similar capsule (containing chromaffin cells) has been observed both in experimental animals and in
15 humans (Aebischer, P., et al., "Transplantation in humans of encapsulated xenogeneic cells without immunosuppression: A preliminary report," Transplantation, 58 § 1275-77 (1994).

Construction of BHK/CNTF Cell Line

A linker generating a SmaI site was introduced at +6 of the mouse
20 MT-I promoter that extended 5' to the natural KpnI site at about -600. This SmaI site was fused to a Klenow-filled XbaI site at the 5' end of a 150 bp XbaI-EcoRI fragment of the murine immunoglobulin region containing parts of exons 1 and 2 encoding the signal peptide and the small intervening intron A. The second exon has an EcoRI site at amino acid 18 of the signal peptide.

25 The human CNTF gene was obtained by PCR amplification of human DNA. A 2700 bp fragment was amplified with primers that included an EcoRI site at the position of the natural hCNTF initiation codon and a BglII site 7 bp 3' of its termination codon. The coding region of the cloned amplification product was sequenced to determine that the open reading frame was intact.

- 23 -

The MT/Ig fragment was fused to the 5' end of the CNTF gene to ensure secretion of the factor. In particular, the hCNTF gene was fused to the MT/Ig sequence via the EcoRI site located in the second exon at amino acid 18 of the Ig signal peptide, such that the sequence starting with amino acid 18 is:

5 Asn-Ser-Ala-Phe-Thr-Glu-His-Ser (SEQ.ID.NO.: 2) where the underlined amino acids represent the amino terminal sequence of hCNTF after the initiating methionine is removed. We believe that the signal peptidase cleaves between Ser and Ala generating a secreted protein identical to full-length hCNTF.

Finally, a 325 bp AvaI fragment of the human Growth Hormone
10 gene (hGH) 3' end, containing the hGH termination codon, 3' UTR and polyadenylation signal sequence, was cloned downstream of the CNTF gene. This was accomplished as follows: A 325 bp hGH AvaI fragment that starts a few bp 3' of the hGH termination codon was then cloned into the SpeI site of Bluescript such that the BamHI site was at the 5' end and the NotI site was at the 3' end. This
15 fragment, which includes the hGH 3' UTR and poly-adenylation sequence, was fused to the BglII site engineered into the 3' end of the hCNTF coding region via a BglII/BamHI fusion.

The entire 3050 bp MT/Ig/hCNTF/hGH KpnI-NotI fragment was then inserted between the KpnI and NotI sites of a pNUT vector in which the
20 EcoRI site was converted to a NotI site by inserting a linker into a Klenow-filled EcoRI site. This vector was named RP3224D.

A 2 kb PvuII fragment containing the HSV-TK gene was cloned into the EcoRV site of Bluescript and the XhoI site was converted to NotI such that a NotI fragment containing the TK gene could be isolated and then inserted into the
25 NotI site of RP3224D to generate the vector named RP3224E2. Figure 8. The sequence of RP3224E2 is given in SEQ.ID.NO.: 1.

The final pNUT-hCNTF plasmid construction, named RP3224E2, was amplified in a standard *E.coli* strain (HB101) and purified by the Qiagen-Plasmid Kit (Kontron).

30 RP3224E2 was transfected into a line of baby hamster kidney cells (BHK) using standard calcium phosphate methodology. Gene amplification was

- 24 -

performed in increasing concentrations of methotrexate (1-200 μM) over 8 weeks to produce stable amplified cell lines. Following this selection, the engineered BHK cells were maintained in vitro in 50-200 μM MTX. No loss of CNTF expression has been observed in the absence of drug selection over three months inclusive, when assayed by Northern Blot analysis, CNTF bioassay, or ELISA for CNTF protein (R&D Systems Inc.).

The encapsulation technique allows the selection of cells over several months for stable expression of the DHFR gene before transplantation. The selected cells can then be analyzed for transgene expression by Northern and Southern blot. The Southern blot analysis revealed the insertion of 38 gene copies for the BHK-hCNTF-tk clone#72, the clone chosen for clinical application.

The level of human CNTF expression from each capsule is tested by ELISA before implantation. For the BHK-hCNTF-tk clone#72, the production of human CNTF was approximately 0.5 $\mu\text{g}/24\text{h}/10^5$ cells. The protein is biologically active as determined by a bioassay on ciliary ganglion neurons and embryonic motoneurons *in vitro*.

Encapsulation

The encapsulation procedure was as follows: The hollow fibers were fabricated from a polyether sulfone (PES) with an outside diameter of 720 μm and a wall thickness of a 100 μm (AKZO-Nobel Wuppertal, Germany). These fibers are described in United States patents 4,976,859 and 4,968,733, herein incorporated by reference. In some studies, including the human study, we used a PES#5 membrane which has a MWCO of about 280 kd. In other studies we have used, or contemplate using a PES#8 membrane which has a MWCO of about 90 kd.

The devices used comprised:

- 1) a semipermeable poly (ether sulfone) hollow fiber membrane fabricated by AKZO Nobel Faser AG;
 - 2) a hub membrane segment;
 - 3) a light cured methacrylate (LCM) resin leading end;
- and

- 25 -

4) a silicone tether.

The semipermeable PES membrane used in the human studies had the following characteristics:

5	Internal Diameter	$500 \pm 30 \mu\text{m}$
	Wall Thickness	$100 \pm 15 \mu\text{m}$
	Force at Break	$100 \pm 15 \text{ cN}$
	Elongation at Break	$44 \pm 10\%$
	Hydraulic Permeability	$63 \pm 8 \text{ (ml/min m}^2 \text{ mmHg)}$
	nMWCO (dextrans)	$280 \pm 20 \text{ kd}$

- 10 The components of the device are commercially available. The LCM glue is available from Ablestik Laboratories (Newark, DE); Luxtrak Adhesives LCM23 and LCM24). The tether material is available from Specialty Silicone Fabricators (Robles, CA). The tether dimensions are 0.79 mm OD x 0.43 mm ID x length 202 mm. The morphology of the device is as follows: The inner surface has a
- 15 permselective skin. The wall has an open cell foam structure. The outer surface has an open structure, with pores up to $1.5 \mu\text{m}$ occupying $30 \pm 5\%$ of the outer surface.

- Fiber material was first cut into 5 cm long segments and the distal extremity of each segment were sealed with a photopolymerized acrylic glue
- 20 (LCM-25, ICI). Following sterilization with ethylene oxide and outgassing, the fiber segments are loaded with a suspension of 2×10^5 transfected cells in a collagen solution (Zyderm® soluble bovine collagen) via a Hamilton syringe and a 25 gauge needle through an attached injection port. The proximal end of the capsule was sealed with the same acrylic glue. In some studies the collagen matrix was
- 25 Zyplast™. The volume of the device used in the human studies was approximately 15-18 μl .

A silicone tether (Specialty Silicone Fabrication, Taunton, MA) (ID: $690 \mu\text{m}$; OD: 1.25 mm) was placed over the proximal end of the fiber allowing easy manipulation and retrieval of the device.

30 In vitro and In vivo Models

The bioactivity of polymer encapsulated BHK-hCNTF-releasing cells was evaluated in a number of *in vitro* and *in vivo* model systems:

- 26 -

1. *In vitro* E14 rat embryonic motoneuron cultures showed an increase in choline acetyltransferase (ChAT) activity upon exposure to capsules containing CNTF releasing cells as compared to capsules containing the BHK parent control line.

5 2. i) facial nerve axotomy model: Facial nerve axotomy in the rat pup induces the loss of motoneurons in the facial nucleus. Systemic delivery of CNTF from encapsulated BHK cells showed a significant rescue effect of the facial motoneurons, compared to capsules containing the parental BHK cell line.

 ii) pmn/pmn model: The pmn/pmn mutant mouse is an animal
10 model of ALS characterized by an autosomal recessive mutation causing progressive motoneuronopathy (Schmalbruch, H., et al., "A new mouse mutant with progressive motor neuronopathy," J Neuropath Exp Neurol, 50; pp. 192-204 (1991)).

 The pmn/pmn mice were examined for grasp activity of the hind
15 paws. As soon as the disease was detected (between 16 and 20 days), the mice received subcutaneous BHK-hCNTF or control BHK cell containing capsules releasing around 0.1 g/day of CNTF.

 Significantly longer survival times (mean 59 ± 1 days) were observed
20 in mice receiving polymer-encapsulated BHK cells secreting CNTF than those receiving capsules containing the parent BHK line (mean 45 ± 3 days). Mice transplanted with hCNTF releasing- capsules also showed diminished motor impairment as compared to mice receiving capsules containing the parent BHK cell line.

Safety Testing

25 One vial from parent cell banks was thawed at passage 28 and amplified to establish a working cell bank, to fully comply with regulatory procedures for use of a recombinant cell line in humans. Ten percent of this bank was then tested for the presence of various pathogens. The working cell bank of BHK hCNTF-tk clone#72 was found to be negative when tested for:

- 27 -

1) amphotropic or xenotropic retrovirus as determined by the *in vitro* detection of murine retroviruses by feline S⁺L⁻ foci;

2) bacterial, fungal and mycoplasma contamination.

The BHK cells were screened for the presence of various pathogens according to the Points to Consider (PTC) cell line safety evaluated guidelines. The cells were found to be free of mycoplasma, pneumonia virus, sendai virus, reovirus type 3, hantaan virus, lymphocytic choriomeningitis and simian virus type 5.

The transmission electron microscopy revealed that the cells contain replication incompetent R particles, and no reverse transcript activity was detected.

Extensive tumorigenicity studies were conducted to evaluate the safety/toxicity of BHK-hCNTF cells implanted in a fully unencapsulated state.

The BHK-hCNTF clone (#72) to be used in human studies was suspended in Ca⁺⁺ Mg⁺⁺-free PBS with collagen matrix at concentrations ranging from 10⁶ - 10⁷ cells/inoculation and injected IP, IT or IVS into nude mice, rats, sheep and primates as summarized in Table 1.

Table 1
Summary of animal models in tumorigenicity studies

animal species	number of BHK-hCNTF-tk clone#72 cells injected	duration	localization injection site
15 rats	1 x 10 ⁶	4 weeks	lateral ventricle
20 4 sheep	1 x 10 ⁷	1 month	lumbar intrathecal
4 sheep	1 x 10 ⁷	3 months	lumbar intrathecal
4 sheep	1 x 10 ⁷	6 months	lumbar intrathecal
4 cynomologus primates	1 x 10 ⁷	1 month	lateral ventricle unilateral injection
25 4 cynomologus primates	1 x 10 ⁷	3 months	lateral ventricle unilateral injection
4 cynomologus primates	1 x 10 ⁷	6 months	lateral ventricle unilateral injection

In summary, unencapsulated BHK cells were rejected in all animals tested. No viable BHK cells were observed in any of the sections examined at the end of the evaluation period. No tumor formation was found after complete gross and microscopic analysis of the cord and brain of these animals.

5 Ganciclovir Sensitivity

1. In vitro studies

Ganciclovir sensitivity was determined on BHK-hCNTF-tk clone#72 in comparison to the polyclonal line not containing the TK gene. The cells were plated at approximately 75,000 cells/well and treated with 3 concentrations (0.02, 10 0.2 and 2 μ M) of ganciclovir. One and 2 days after plating, cells were treated with fresh ganciclovir and the effect was determined after 4 days. No effect of ganciclovir was observed on the polyclonal line of BHK-hCNTF cells (tk-) at any concentration. For the BHKhCNTF-tk clone#72, no effect was observed at 0.02 μ M of ganciclovir, 95-100% of population were eliminated in presence of 0.2 μ M and 15 100% of the cells were killed in the presence of 2 μ M.

Experiments were performed to determine whether there is a significant bystander killing effect (i.e., if some cells stop expressing the TK gene, do they escape the activated drug) on the BHK-hCNTF when combined with different ratios of ganciclovir-sensitive BHK-hCNTF-tk cells.

20 Cells were mixed at a 1:2, 1:5, and 1:10 ratio of BHK-hCNTF-tk clone#72 cells to the (tk-) BHK-hCNTF cells. Cultures were treated with fresh ganciclovir (2 μ M) on day 1 and 4. Cells at the 1:10 ratio received an additional dose on day 7. The results indicated a robust bystander killing effect when BHK-hCNTF-tk cells are mixed with BHK-hCNTF cells. Following 3-4 days of 25 exposure to 2 μ M of ganciclovir, greater than 95% of the 1:2 and 1:5 ratio cells were killed and by the 5th day, 100 % of the cells were killed. Following 8 days and 3 treatments of 2 μ M of ganciclovir, less than 0.1% of the cells remained at the 1:10 ratio.

2. In vivo studies

The in vivo efficacy of the tk system was tested in a nude mouse model. The nude mouse is a highly stringent model allowing to test the sensitivity of the BHK-hCNTF-tk clone#72 cells in the absence of T-cell mediated
5 immunological response. Thirty animals were used, 10 for each of the following conditions.

Group 1 received ganciclovir 50 µg/kg, by injection two times a day (BID) for 5 days. Group 2 received inoculations of 1×10^6 BHK-hCNTF-tk cells suspended in 100 µl and saline (vehicle) injections BID for 5 days. Group 3
10 received inoculations of BHK-hCNTF-tk cells ($1 \times 10^6/100 \mu\text{l}$) and ganciclovir injections (50 mg/kg) BID for 5 days. In all groups, the animals were weighed once per week during the entire 4 week evaluation. The animals were also monitored for the appearance of the tumor nodules as well as for their overall health. Histological analysis for the presence of subcutaneous nodules on their bodies were performed
15 immediately after sacrifice.

No tumors were observed in the control group 1 after 4 weeks. These animals gained weight during the experiment. In Group 2, tumor formation was observed in 9 out of the 10 mice after 1 week. The nodules ranged in size from 5 to 10 mm in diameter. Five mice died by 4 weeks. Four were moribund and
20 weighed approximately half of those animals in group 1. The mouse that remained nodule-free through the 4 weeks experiment appeared to be in generally good health. Small nodules were observed at 4 weeks in 5 of the 10 mice of group 3. None of the 10 animals became sick and all of them gained weight during the course of the experiment.

25 We conclude that the BHK cells are tumorigenic in nude mice and the subcutaneous nodules were in all cases localized to the site of injection. Although the data suggest that the BHK-hCNTF-tk cells are sensitive to ganciclovir *in vivo*, the collaboration between ganciclovir treatment and a natural immunity to these xenogeneic cells is likely to be necessary for the complete elimination of these
30 BHK cells especially when coupled to a BID delivery of ganciclovir.

Toxicity studies

a) CNTF toxicity study in rat

In our trial, we proposed delivery of 0.25-1 μg of CNTF intrathecally per day to humans. In order to test the potential toxicity of CNTF delivered intrathecally, we implanted rats with polyether sulfone ("PES") devices in the intrathecal space.

Rats received a 20 mm long PES#5 capsules loaded at 2×10^5 cells of the BHK-hCNTF-tk clone#72 or clone#39. The hCNTF released by each device was measured by ELISA. The amount of hCNTF delivered by the devices loaded with the clone#72 and clone#39 was 5 and 1.2 $\mu\text{g}/\text{day}/10^6$ cells, respectively. As the rats weighed around 300 gr, they received more than 400 times more CNTF than the amount we proposed delivering to humans.

The capsules were placed in the subarachnoid space over the spinal cord through a laminectomy performed at the LI-L2 level. The animals were then closely observed during the course of the implantation monitoring rectal temperature, weight and general behavior. Cerebrospinal fluid (CSF) was collected at the time of sacrifice for CNTF determination through an occipital tap. The retrieved capsules were fixed in a 4 % paraformaldehyde (PAF) solution. The animals were transcardially perfused with a 4 % PAF solution. The spinal cord was inspected in situ and dissected for complete histologic analysis. Biocompatibility and viability of the encapsulated cells was assessed on glycolmethacrylate sections. Potential toxicity of hCNTF on nervous tissue was assessed on frozen sections of the spinal cord analyzing the general morphology by Nissl stain, the astrocytic reaction by GFAP and the microglia reactivity by immunohistochemistry. The following results have been obtained on:

	i)	<u>Rats implanted with BHK-hCNTF-tk clone#39</u>
	Cell type	clone#39
	No. of rats	5
	Capsule Type	PES#5
30	Cell Loading	2×10^5 cells

Implantation Duration	7 days
ELISA	at day 1 after loading at day 7

5 The CNTF released by each capsule was measured one day prior to
implantation by ELISA. Five rats were implanted with these capsules for 7 days.
No adverse effect was observed on the general behavior of the implanted animals
and no significant variation of the animal's weight or temperature was seen. For
comparison the intraventricular delivery of 2.4 to 60 μ g of BDNF per day induces a
10 10 to 20 % weight loss over one week (Yan, Q., et al., "The biological responses of
axotomized adult motoneurons to brain-derived neurotrophic factor," J Neurosci,
14; pp. 5281- 5291, (1994)). More CNTF was released at explant as compared to
preimplant value (0.37 ± 0.11 vs 0.62 ± 0.15 μ g/day respectively).

15 The retrieved capsules were devoid of any macroscopic tissue
adhesion. The microscopical evaluation of the capsules revealed excellent
biocompatibility, with only a few isolated cells adhering to the device. Histological
examination of the spinal cord showed no gross reactivity. The meninges appeared
normal. Neuronal populations, especially the ventral horn motoneuron population
were of normal appearance. Only minimal GFAP and microglia reactivity was
20 observed.

ii) Rats implanted with BHK-hCNTF-tk clone#72

	<u>experiment 2A</u>	<u>experiment 2B</u>
Cell Type	clone#72	BHK
No. of rats	8	6
Cell Loading	2×10^5 cells	2×10^5 cells
25 Implantation Duration	1 month (33 days)	1 month (33 days)
ELISA	at day 5 at the time of sacrifice	at day 5 at the time of sacrifice

- 32 -

The CNTF released by each capsule was measured by ELISA before implantation. Eight animals were implanted for one month. At the same time, 6 animals received capsules loaded with the parent BHK cell line.

No modification of the behavior or temperature was observed in any of the implanted animals. All animals gained weight over the experiment, however, rats implanted with the clone#72 gained weight slower than the control rats. No other difference was observed between the animals receiving CNTF capsules versus the control ones. The animals were sacrificed 33 days post-implantation. The morphological appearance was identical to that described with the clone#39.

10 b) Toxicity study of the various
 types of capsules in the sheep

Six sheep were implanted intrathecally with polyether sulfone-based capsules, substantially as described above, containing the above-described BHK/CNTF cells. The 5 cm long capsules were implanted in the sheep lumbar subarachnoid space as previously described (Joseph, J.M., et al., "Transplantation of encapsulated bovine chromaffin cells in the sheep subarachnoid space: a preclinical study for the treatment of cancer pain," Cell Transpl, 3; pp. 355-364 (1994)). The cell density was 50×10^3 cells/ μ l for all animals. The capsules were left in place for one month in all animals. CSF was collected at the time of implant, 8 days postimplantation and at the explantation time. Both cellularity and protein level were analyzed.

The histological analysis of the explanted capsules showed the presence of viable BHK cells surrounding a core of non-viable cells. No systemic toxicity as assessed by behavior, rectal temperature or weight measurement was observed. A strong GFAP reactivity was present in animals which had adhering or intramedullary implants. In contrast, the GFAP reactivity was small in animals with "free floating" capsules. Nissl stain showed normal neuronal cellularity in all animals.

The CSF analysis revealed both an increase of cellularity and protein concentration 8 days post-implantation as compared to the pre-implant level. This increase however returns to normal at 4 weeks.

Human Clinical Trial

Ten patients were selected with relatively good muscle strength and forced vital capacity. Each patient was to be evaluated with a standardized scoring system for three months prior to entry and then implanted with a device. A five
5 centimeter membrane-based implant, containing approximately one million BHK cells producing CNTF, as described above, was placed into the lumbar intrathecal space of each patient under local anesthesia.

Our goal was to produce a modest, but measurable amount of CNTF in the CSF, and to show that this could be done with few of the side effects that
10 troubled the Regeneron and Syntex/Synergen trials.

According to our protocol, following a three month evaluation for safety, the device was to be explanted and measured for cell viability and CNTF production. Upon the request of the patient, a new device could be implanted and the patient could then be followed for a further 6 months. Plasma as well as CSF
15 levels of CNTF were measured and serum samples were also drawn and analyzed to determine whether an immune reaction was generated against the BHK cells that were in the capsule and producing CNTF. Patients were rechecked for performance against the motor scale that had been used to evaluate them during the three month run in period and queried for side effects.

20 Protocol

Patient recruitment was based on the following criteria:

a) Entry criteria:

- (1) A diagnosis of ALS as manifested by a combination of both upper and lower motoneuron deficits at multiple levels;
- (2) Confirmatory
25 electrophysiologic studies demonstrating active and chronic denervation in 3 limbs or 2 limbs and bulbar musculature;
- (3) Forced vital capacity (FVC) > 75% normal at entry;
- (4) Relatively strong patient (i.e. can walk by himself);
- (5) Patient early in the course of the disease;
- (6) Written informed consent.

- 34 -

b) Exclusion criteria

- (1) Patient with a life threatening illness (eg, cancer, leukemia) in addition to ALS; (2) Pregnant woman or woman of child-bearing potential without adequate contraception; (3) Patient with neurological involvement outside the voluntary motor system; (4) Evidence of primary disease that could cause neurologic deficit (in particular, cervical spondylosis or plasma cell dyscrasia); (5) Patient participating in any investigation drug trial running concurrently to this trial.

Clinical evaluation before treatment

The patients admitted in the trial were submitted to a general examination before the implantation, as follows:

1. General clinical examination including an evaluation of general appearance, skin and subcutaneous tissue, eyes, ears, nose, throat, neck (including thyroid), chest (lung), heart, liver, musculo-skeletal, spleen, peripheral vascular, abdomen, neurological (other than ALS);
2. Neurological examination including:
 - a) TQNE (Tufts Quantitative Neuromuscular Examination), a quantification of the isometric force evaluating:
 - i) Bulbar Coordination: "PA": 20 repetitions and "PATA": 15 repetition;
 - ii) Fine Motor Skills;
 - iii) Maximal isometric force: shoulder flexion (antiflexion); shoulder extension (retroflexion); elbow flexion; elbow extension; grip; hip flexion; hip extension; and foot dorsiflexion.
 - iv) Respiration function: FCV (force vital capacity); MVV (maximal voluntary ventilation); MEVS (maximal expiratory volume per second); PI max (maximal inspiratory pressure), PE (maximal expiratory pressure); and SNIP (sniff nasal inspiratory pressure).
 - b) Ashworth scale including a Muscle Tone Spasticity Scale and a Myotic Reflex Scale

- 35 -

- i) The Muscle Tone Spasticity Scale: (0. Absent; 1. Weak improvement of muscle tone involving little resistance to flexion or extension; 2. Moderate Resistance to extension; 3. Considerable resistance, passive movement difficult; 4. Limb in rigid flexion or extension);
- 5 ii) Myotic Reflex scale: (0. Absent; 1. Diminished, but present; 2. Normal; 3. Increased, with extension of the reflexogenic zone; clonic reflex);
- c) Barthel index: a quality of life scale based on meals, bathing, personal hygiene, dressing, sphincter control, bladder control, toilet used, 10 wheelchair used, walking, staircase. Functional Life, Bartel Index, (Mahoney and Barthel, 1995).
3. Paraclinic examination including:
 - a) Blood work: hematology and biochemistry
 - b) Urine work (examination of proteins and leukocytes).

15 Implantation:

Six ALS patients have been implanted and are currently being treated in Lausanne, Switzerland. Four more patients were implanted in late September 1995. For the first patients, after three months of treatment, cells were removed and found to be still viable and producing CNTF. A new set of cells 20 replaced the first set and patients are continuing for another three months. The cells continuously produce about 0.5-1 μg of CNTF per day, which is about 30-4000-fold less than doses used in previous CNTF trials. The first ten patients received a 5 cm long intrathecal implant.

Surgical procedure:

25 Infection prophylaxy with 2g cefazolin (Kefzol®) IV. Premedication with midazolam (Dormicum®) IV.

Under local anesthesia (xylocain 1%) a cranio-caudal skin incision of 3 cm is performed at the L4-L5 level. Section the subcutaneous tissue down to the dorsal fascia.

- 36 -

Puncture the subarachnoid space with a 25G Tuohy needle and withdraw 12 ml of CSF. Introduction of a guide wire through the needle which is then retrieved. Introduction of a dilator for the *ligamentum flavum* widening over the guide wire. Retrieval of the dilator and introduction of a cannula (4F) over the
5 guide. Retrieval of the guide wire. The capsule is then pushed through the cannula and positioned in the subarachnoid space. The cannula is retrieved. See, e.g., WO 94/15663.

Fixation of the silicone tether at the lumbar fascia with a 4-0 polypropylene (Prolene®). Skin closure with interrupted 4-0 nylon suture
10 (Dermalon®).

For the retrieval of the device at 3 months, the skin is re-opened at the same place and the 4-0 polypropylene section. The capsule is retrieved by gentle pulling on the silicone tether. The biocompatibility, the histology and the CNTF release of the explanted capsule are examined before re-implanting of a new
15 device in the patient, following the same protocols.

Evaluation and follow-up

The patients were evaluated once a day during the first 4 days. We have monitored patients for side effects such as cough, weight loss, somatitis, asthenia, and fever, which were the main effects observed in the halted systemic
20 CNTF trials. In addition, the following tests were performed after the implantation of the device.

At 1 and 2 weeks we measured hematology, including red blood cell count, hemoglobin, hematocrit, white blood cell count (neutrophils, lymphocytes, eosinophils, basophils and monocytes), platelets, PT, PTT, fibrinogen, C reactive
25 protein, and sedimentation rate. We also conducted biochemistry analysis of glucose, total bilirubin, direct bilirubin, SGOT(ASAT), SGPT (ALAT), gamma GT, alkaline phosphatase creatinine, albumin, protein, urea, and calcium.

At 4 and 8 weeks we performed the same hematology and biochemistry analysis as above. We also examined vital signs, including supine
30 heart pressure and supine blood pressure (5 min.).

- 37 -

We also measured scores on a standardized test developed to measure the clinical deficit and progression of ALS. The test battery, developed by the Neuromuscular Research Unit at the New England Medical Center is referred to as the Tufts Quantitative Neuromuscular Exam or TQNE. See, Andres et al. Neurology, 38; pp. 409-413 (1988). The TQNE is a validated test battery specifically designed to measure the motor function and strength of ALS patients as the disease progresses.

The battery includes testing of five major functional areas: bulbar, respiratory, arm, leg, and fine motor activities. The TQNE test battery consists of 28 qualitative items that assess motoneuron function at different levels of the neuraxis. In this way, one can predict the patient's individual course of the disease on the basis of 3 successive tests 1 month apart.

We also measured scores on the Ashworth scale test, including: Muscle Tone Spasticity scale (Ashworth, 1964) (0. Absent; 1. Weak improvement of muscle tone involving little resistance to flexion or extension; 2. Moderate resistance to extension; 3. Considerable resistance, passive movement difficult; 4. Limb in rigid flexion or extension).

Measurements of Myotic Reflex were also taken (0. Absent; 1. Diminished but present; 2. Normal; 3. Increased, with extension of the reflexogenic zone; clonic reflex).

At 12 weeks we explanted the devices, and again made TQNE, Ashworth scale, hematology, biochemistry, and vital signs measurements. The explanted capsules were replaced by new capsules. CNTF released from each explanted capsule was determined using an ELISA assay for CNTF protein. Histology was performed on all explanted capsules.

At 16, 20, 24 weeks we made TQNE, Ashworth scale, hematology, biochemistry, and vital signs measurements. We also assessed patients according to the Norris scale. This scale is described in Norris et al., "The administration of guanidine in amyotrophic lateral sclerosis", Neurology, 24, pp. 721-28 (1974).

Serum results for the first three patients, implanted on March 15, 1995 are shown in Table 2.

Table 2
P238-95 anti-BHK(CNTF) Human Trials
Serum Flow Cytometric crossmatch

Patient	sample #1 1/10/95	sample #2 4/20/95	sample #3 5/4/95	sample #4 5/30/95	sample #5 6/15/95	Comments	
5	1. AB anti-IgM	+ ^a	+	+	+	+	no change
	AB anti-IgG	+	↑ ^b	↓ ^c	+	+	transient increase at day 9 only
	2. CM anti-IgM	+	+	+	+	+	no change
	CM anti-IgM	neg	neg	neg	neg	neg	no anti-IgG detected
	3. GM anti-IgM	+	+	+	+	+	no change
10	GM anti-IgG	+	+	+	+	+	no change

^a + positive at baseline; ^b ↑ increase over baseline value;
^c ↓ return to baseline value

The results of our trial were quite clear. No significant side effects occurred. Non-serious side effects included mild cough and some asthenia.

15 Consistent measurable levels of hCNTF (between .25 - 6.3 ng/ml) were produced in the CSF in patients 1-5 (Fig. 1; Table 3). No hCNTF was detectable in the plasma. The sixth patient has had a sample drawn, but the assay has not yet been run. The second set of patients had capsules implanted that were expected to produce slightly more CNTF than the first set of three patients. The first three patients had samples
 20 drawn at 10 weeks and then 12 weeks to determine whether the CSF level would remain stable.

Table 3

CSF ANALYSIS

weeks	hCNTF [pg/ml]	hCNTF [pg/ml]		
		patient 1	patient 2	patient 3
5	0	0	0	0
	11	320	170	810
	13	500	240	710

weeks	hCNTF [pg/ml]	hCNTF [pg/ml]		
		patient 4	patient 5	patient 6
10	0	0	0	0
	7	3847	2490	not done
	10	666	2135	1420
	17	6282	967	224

Upon explant, the capsules had viable cells still producing CNTF (Table 4).

Table 4

CAPSULE ANALYSIS

15	time (weeks)	patient 1		
		patient 2	patient 3	
Implant (µg/24h)	0	0.589	0.636	
Explant (µg/24h)	13	0.194	0.196	

	time (weeks)	patient 4		
		patient 5	patient 6	
Implant (µg/24h)	0	0.137	0.125	
Explant (µg/24h)	17	0.833	0.154	

- 40 -

There was no attempt to re-equilibrate to baseline conditions. Nonetheless, the intracapsule consistency was very good. Re-equilibration is normally carried out for 24 hours under the original baseline conditions.

No antibody reaction was noted against the BHK cells (see Table 2).

5 Fig. 2 shows C reactive protein and fibrinogen were variable, but at the beginning and end of the experiment the values were quite close to their baseline values. There was no evidence for either an acute or sustained effect. Neutrophils and lymphocytes did not vary over the three plus month period under study (Fig. 3). Total wbc and ESR remained within the normal range throughout the study (Fig.
10 4).

On the patients measured so far, weight was constant throughout the study. (Fig. 5).

The first three re-implanted patients were rechecked for CNTF CSF levels. Patients 1 and 3 had detectable levels, patient 2 did not. This patient was
15 rechecked for a CSF level. Fig. 6. The device was explanted to check for viability. No viable cells were found in the device.

Fig. 7 shows the Norris scores on patient 1 (Panel A), patient 2 (Panel B), patient 3 (Panel C), patient 4 (Panel D), and patient 5 (Panel E).

Reimplantation could be successfully performed. We are not seeing
20 the early acceleration of ALS symptoms that troubled the Regeneron trial. So far all patients have requested reimplantation.

Example 2

In this study, we evaluated the use of C₂C₁₂ mouse myoblasts. Myoblasts have all the advantages of a rapidly dividing cell line while having the
25 potential of differentiating into non-dividing myotubes upon exposure to low serum containing media. Myoblasts can easily be manipulated and transfected *in vitro*, they can be differentiated into non-mitotic cells, and they have been shown to express, process and secrete a transgene product both before and after differentiation. Mouse C₂C₁₂ myoblasts were transfected with a pNUT expression vector containing
30 the human ciliary neurotrophic factor (CNTF) gene. hCNTF expression and

- 41 -

bioactivity was demonstrated by Northern blot, Elisa assay, and measurement of choline acetyl transferase (ChAT) activity in embryonic spinal cord motoneuron cultures. One C₂C₁₂ clone was found to secrete 200 ng CNTF/10⁶ cells/day. The rate of secretion of hCNTF was not altered upon differentiation of C₂C₁₂ myoblasts.

5 A BrdU proliferation assay indicated that approximately 12% of the myoblasts continue to divide after 4 days in low serum containing medium. The presence of the herpes simplex thymidine kinase gene (HSV-tk) in the expression vector, however, provides a way to eliminate these dividing myoblasts upon exposure to ganciclovir, therefore increasing the safety of the encapsulation technology using

10 established cell lines. Encapsulated hCNTF- C₂C₁₂ cells can partially rescue motoneurons from axotomy-induced cell death. In adult rats, intrathecal implantation of encapsulated hCNTF-C₂C₁₂ cells or control C₂C₁₂ confirmed the long-term survival of these cells and their potential use as a source of neurotrophic factors for the treatment of neurodegenerative diseases.

15 Vector construction:

The expression vector RP3224E2 contains the entire human CNTF gene as described above. The RP3224D plasmid, which is identical to RP3224E2, but carries no HSV-tk gene, was modified as follows. RP3224D was digested with the restriction enzymes Sall and ClaI to remove the dihydrofolate reductase gene

20 (DHFR) as well as the Hepatitis virus B 3' untranslated region (HBV-3' UTR). The purified vector was filled in by using the Klenow fragment. The neomycin resistance gene and the SV40 promoter were excised from a pNUT/neo plasmid (Dr. E. Baetge, CytoTherapeutics, Inc., Providence, USA) with the restriction enzymes HindIII and BamHI. The isolated fragment was blunted by filling in the protruding

25 ends with T4 DNA polymerase and subcloned into the Sall/ClaI RP3224D vector. The resulting plasmid pNUT-hCNTF-N was further modified to introduce the herpes simplex virus thymidine kinase gene (HSV-tk) (NotI fragment isolated from the RP3224E2) at the unique NotI site. The construct was named

30 pNUT-hCNTF-NT. The vector pNUT-hCNTF-DNT was constructed by inserting the neomycin resistance gene under the control of the SV40 promoter (BamHI-NotI

- 42 -

fragment from pNUT/neo filled in with the Klenow enzyme) into the blunted KpnI site of the RP3224E2 expression vector. Figure 9.

Cell culture conditions and transfections:

C₂C₁₂ mouse myoblasts, derived from leg skeletal muscles of an adult C3H mouse were obtained from American Type Culture Collection (ATCC, CRL 1772, Rockville, MD). C₂C₁₂ cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS), 2 mM L-glutamine, 4.5 g/l glucose, 100U/ml penicillin, 100U/ml streptomycin. Differentiation of C₂C₁₂ myoblasts into post-mitotic myotubes was carried out by exposing the confluent myoblast cultures to DMEM with 2% fetal calf serum for 3-4 days. The cells were maintained in the incubator at 37°C and 5% CO₂. The plasmid pNUT-hCNTF-NT was transfected into the C₂C₁₂ mouse myoblast cells by electroporation (0.3 KV, 960 mF; Bio rad). The transfected cells (5x10⁶ cells) were then exposed to 1mg/ml G418 (Sigma) for selection. The hCNTF-C₂C₁₂ clone #15 was obtained by limiting dilution. C₂C₁₂ cells transfected by calcium phosphate precipitation (Mammalian transfection kit, Stratagene) with the pNUT-hCNTF-DNT plasmid were selected with 0.8 mg/ml G418 for two weeks, and the integrated plasmid was then amplified with increasing concentrations of methotrexate (1-200 μM) over a 6 weeks time period. One clone (#3) producing approximately 2 μg hCNTF/10⁶ cells/day was obtained by limiting dilution.

Northern blot analysis:

A BamHI fragment (546 bp) from the RP3224E2 plasmid corresponding to the 3' end of the hCNTF gene was subcloned into pBluescriptSK⁻ plasmid (Stratagene). The plasmid pSp65BAC was obtained by inserting a 200 bp (PstI-BglII) fragment of the mouse β-actin cDNA into the pSp65 vector (Promega Biotech) (Jongeneel *et al.*, J. Immunol., 140, pp. 1916-22 (1988)). To prepare radiolabeled anti-sense RNA probes, the plasmids pBluescriptSK⁻-hCNTF and pSp65BAC were linearized using appropriate enzymes and transcribed *in vitro* with T3 or Sp6 RNA polymerase (Promega Biotech) and α-³²P-UTP (Amersham).

Fifteen μg of total cytoplasmic RNA were used for Northern blot analysis as described previously (Dégion *et al.*, Eur. J. Biochem., 231, pp. 687-96 (1995). Briefly, the filter was hybridized with 1×10^6 counts per minute per ml (cpm/ml) of anti-sense RNA probes for 48 hours at 55°C in the hybridizing solution. The filters
5 were washed 4 times for 15 minutes each time in $0.1 \times \text{SSC}$, 0.1% SDS at 60°C . Densitometric analysis of several autoradiograms with different exposure times was performed using a ScanJet IIcx scanner (Hewlett Packard) and the DeskScan II and Scan Analysis softwares. Normalization of the steady state level of CNTF and actin expression was performed using the 28S RNA probe.

10 *In vitro* ChAT bioassay:

The bioactivity of hCNTF released from the various C_2C_{12} clones was determined *in vitro* using cultures of ventral spinal cord from E14 embryonic rats. Motoneurons were prepared as described by Martinou *et al.*, Neuron, 8, pp. 737-44 (1992). A dose response curve with recombinant hCNTF (Calbiotech,
15 Mountain View, CA) was used as a positive control. Conditioned medium was obtained by exposing either the parent C_2C_{12} cells or the hCNTF- C_2C_{12} cells (1.8×10^5 cells per well) to 2 ml of embryonic motoneuron culture medium for 12 hours. Embryonic rat motoneuron cultures were grown in the presence of $50 \mu\text{l}$ of conditioned medium which was replaced every 2 days. After one week *in vitro*, the
20 choline acetyltransferase (ChAT) present in the cultures was determined by measuring the production of ^3H acetylcholine from ^3H acetylcoenzyme A (Beretta and Zurn, Dev. Biol., 148, pp. 87-94 (1991)). Results are given in cpm of ^3H -acetylcholine formed per 20 minutes and per culture. Activity measured from each well was normalized to the cpm counts of the control wells that did not receive
25 any trophic factor, and is represented as a percentage.

ELISA assay:

Parent C_2C_{12} cells or hCNTF- C_2C_{12} (clone #15) cells were plated at a density of 1×10^5 cells per well for twelve hours on 6-well tissue culture dishes (Costar) in PC-1 medium, a serum free medium containing human recombinant

- 44 -

proteins (Hycor Biomedical Inc., CA). Conditioned media were obtained by incubating the cells encapsulated or not in 2 ml of fresh PC-1 medium for 30 minutes. These samples were then stored at -20°C until tested using an ELISA kit for hCNTF (R&D Systems, Minneapolis, MN).

5 5-bromo-2'-deoxy-uridine proliferation assay (BrdU):

Parent C₂C₁₂ cells or hCNTF-C₂C₁₂ (clone #15) cells were cultured for 4 days in complete DMEM or differentiating medium. The cell proliferation was measured by determining the incorporation of BrdU (BrdU labelling and detection kit II, Boehringer Mannheim). The cells were incubated at 37°C, 5% CO₂ for 60
10 min with 10 μMol/l BrdU labelling medium. The samples were fixed with 70% ethanol and incubated 30 min with anti-BrdU mouse monoclonal antibody (clone BMC 9318, IgG1). After 30 min incubation with anti-mouse-Ig-alkaline
phosphatase and addition of color-substrate solution (nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate), the bound anti-BrdU monoclonal antibody
15 was visualized by light microscopy. The percentage of labelled cells were counted using a phase-contrast Zeiss Axiovert 100TV microscope at 50-100x. Five to seven visual fields were counted from each culture well. Results were obtained from two separate experiments, each performed in triplicate.

Sensitivity to ganciclovir:

20 Control C₂C₁₂ or C₂C₁₂ cells transfected with the pNUT-hCNTF-DNT vector were plated at a density of 2 x 10⁵ cells per well on 6-well tissue culture dishes (Costar). C₂C₁₂ myoblast differentiation was induced by exposing the culture to DMEM containing 2% FCS for 3 days. Non-differentiated C₂C₁₂ and hCNTF-C₂C₁₂ were plated at a density of 1 x 10⁴ cells per well at the
25 beginning of ganciclovir treatment. Fresh ganciclovir solution (Cytovene* Syntex) at a final concentration of 5 μM was added to the cultures for 5 days. Results were evaluated by microscopic examination.

Encapsulation:

Control and transfected C₂C₁₂ cells were harvested using 0.125% trypsin. Dilutions were made to achieve a suspension of 1 x10⁵ cells/ μ l in 1.75 mg/ml Zyderm (Collagène S.A., Lausanne, Switzerland). The cell suspension was then injected into microporous polyethersulfone hollow fibers (OD: 550 μ m, ID: 350 μ m) (Akzo Nobel Faser AG, Wuppertal, Germany). One centimeter long capsules were made by cutting them to appropriate lengths and heat sealing the ends. Each capsule contained approximately 2x10⁵ cells at the time of encapsulation. Capsules were kept in DMEM medium containing 10% FCS in an incubator at 37°C and 5% CO₂ for two days prior to differentiation in low serum medium for 3 days. Capsules were then transferred to PC-1 medium and subsequently tested using the *in vitro* bioassay and the ELISA assay.

Facial nerve axotomy in neonatal rats:

Postnatal day 2 (P2) Sprague Dawley rat pups (IFFA-Credo, France) were anesthetized by hypothermia. The facial nerve was then transected unilaterally at about 1 mm from the stylomastoid foramen. Capsules containing either control or hCNTF releasing C₂C₁₂ cells were implanted subcutaneously. A small puncture in the dura was made to open the blood brain barrier of the animals. One week post-implantation, each animal was perfused transcardially under pentobarbital anesthesia and fixed in 4% paraformaldehyde with 1% glutaraldehyde. The brain stems were removed and post-fixed overnight before processing for paraffin blocking. Serial sections, 7 μ m thick, were cut throughout the entire brain stem and motoneuron counts were performed on every fifth section as described by Sendtner *et al.* Nature, 345. Pp. 440-41 (1990) at a 100x magnification. The percent survival is represented as the number of motoneurons counted on the lesioned side divided by the number on the contralateral side.

Intrathecal capsule implantation in adult rats:

Adult male Wistar rats weighing 280 to 360g (IFFA-Credo, France) were anesthetized using intraperitoneal injection of pentobarbital (50 mg/kg).

- 46 -

Animals were placed in a prone position for surgery. A L1 laminectomy was performed with a 1.5 cm sagittal lumbar incision, and the dura mater opened. Capsules were carefully placed in the subarachnoid space. The incisions were closed using resorbable sutures. Upon recovery, the animals were returned to the animal care facility where they had access to food and water *ad libitum*. Animals were re-anesthetized following the 3 months viability study and the capsules were explanted using the same technique as described above.

Capsule histology:

Capsules kept *in vitro* and those retrieved from *in vivo* experiments were fixed in 4% paraformaldehyde with 1% glutaraldehyde overnight and dehydrated under alcohol cycle in preparation for glycol-methacrylate embedding (Leica). The capsules were cut at 6 μm thickness and stained with cresyl violet.

Analysis of hCNTF gene expression:

C_2C_{12} cells transfected with the pNUT-hCNTF-NT expression vector were selected for G418 resistance. Several clones isolated by limiting dilution were analyzed by Northern blot. Clone #15 was selected for further characterization. A messenger RNA of 1.2 kb corresponding to the human CNTF was observed in the transfected cells whereas no signal was obtained when 15 μg of RNA from the control C_2C_{12} cells was loaded on the gel. After removal of the drug selection for one month a significant amount of CNTF mRNA was still measured. Similar results have been obtained with another hCNTF- C_2C_{12} clone maintained for 3 months without G418, confirming the stability of transgene expression in myoblasts. To determine whether C_2C_{12} cells cultured in DMEM medium containing 2% serum during 4 days are differentiated, the same filter was hybridized with an actin anti-sense RNA probe. A typical increase in the transcript coding for muscle α -actin is observed in C_2C_{12} and hCNTF- C_2C_{12} cells maintained in differentiating medium (Dhawan *et al.*, Science, 254, pp. 1509-12 (1991)). Differentiation is also accompanied by the appearance of multinucleated cells. Densitometric scanning of the Northern blot and normalisation of the results with the 28S RNA probe indicate

- 47 -

that differentiation of C₂C₁₂ cells does not significantly decrease the amount of hCNTF mRNA produced by the cells. Conditioned media from C₂C₁₂ or hCNTF-C₂C₁₂ cells were analysed for the presence of secreted hCNTF using a two site enzyme immunoassay. The average secretion rate of hCNTF-C₂C₁₂ cells (clone #15) is 200 ng hCNTF/10⁶ cells/day. The bioactivity of the produced hCNTF was evaluated using embryonic rat ventral spinal cord cultures, and measuring changes in neuronal ChAT activity in the presence or the absence of the ciliary neurotrophic factor. Results confirm that the transfected C₂C₁₂ myoblasts produce a bioactive hCNTF. ChAT activity in cultures exposed to conditioned media from hCNTF-C₂C₁₂ cells was comparable to that obtained following a single application of 20 ng/ml recombinant hCNTF. The ChAT bioassay also demonstrates that C₂C₁₂ cells continue to secrete hCNTF following differentiation.

BrdU proliferation assay:

In order to determine the percentage of post-mitotic C₂C₁₂ cells pre- and post-differentiation *in vitro*, a 5-bromo-2'-deoxy-uridine (BrdU) proliferation assay was performed. Following a one hour incubation with BrdU, 81.3 % ± 8.9% and 79.2% ± 9.5% of the C₂C₁₂ and hCNTF-C₂C₁₂ cells were labelled respectively. This percentage decrease to 11.8 % ± 5.4 % and 13.1% ± 6.1% after 4 days of culture in differentiating medium.

Herpes Simplex Virus Thymidine Kinase expression:

The ability to eliminate non-differentiated C₂C₁₂ cells *in vitro* or *in vivo* would add a level of safety for clinical use. The herpes simplex virus thymidine kinase gene (HSV-tk) was therefore included in the expression vector (Figure 9), rendering the proliferating hCNTF-C₂C₁₂ cells susceptible to ganciclovir mediated destruction. hCNTF-C₂C₁₂ cells cultured in complete DMEM medium are killed by the addition of 5 μM ganciclovir, whereas the parent C₂C₁₂ cells are not affected by the treatment. As expected from the BrdU results with the proliferation assay, a small percentage of the hCNTF-C₂C₁₂ cells maintained during 5 days in differentiating medium are destroyed by the addition of ganciclovir. This ganciclovir

- 48 -

sensitivity is not due to the differentiation process as the differentiated parent C₂C₁₂ cells are not affected by the treatment.

Motoneuron survival after lesion of the facial nerve in newborn rats:

The neonatal rat axotomy model was used to evaluate the efficacy of
5 our hCNTF delivery system. Immediately following the axotomy of the facial nerve,
newborn rats (P2) were implanted subcutaneously with polymer capsules containing
either control C₂C₁₂ cells or hCNTF-transfected myoblasts. Morphological study of
the facial nuclei was performed 1 week post-axotomy. Control animals retained
only 16.3 ± 0.3% (n=6) of their facial motoneurons after one week whereas a
10 continuous release of hCNTF resulted in 23.6 ± 3.5% (n=10) survival of the
motoneurons. Histological sections through one of the retrieved capsules
containing hCNTF-C₂C₁₂ cells was performed. Viable C₂C₁₂ cells were observed
throughout the entire device in both control and transfected cells. A longitudinal
alignment of the C₂C₁₂ cells was observed.

15 **Long-term *in vivo* studies:**

To evaluate the long-term survival and the transgene expression of
immunoprotected C₂C₁₂ cells, C₂C₁₂ (n=6) and hCNTF-C₂C₁₂ cells (n=6) were
encapsulated, differentiated *in vitro* during for 4 days and implanted into the
subarachnoid space of rats. CNTF secretion, pre- and post-implantation, was
20 measured by an ELISA assay. All devices containing transfected C₂C₁₂ cells
produced significant amounts of hCNTF upon retrieval. Microscopic examination of
the retrieved capsules confirmed the excellent viability of C₂C₁₂ cells 3 months
post-implantation. Cells clusters entrapped in the collagen matrix are distributed
throughout the capsule and no accumulation of cell debris is observed. Similar
25 results were obtained with hCNTF-C₂C₁₂# 3 cells.

The present study suggests that polymer capsules containing
hCNTF-secreting C₂C₁₂ cells can serve as a long-term delivery system within the
CNS. *In vitro*, the secretion of bioactive hCNTF was not altered following
differentiation of the myoblasts into myotubes. Further analysis of the differentiated

C₂C₁₂ myoblasts demonstrated the typical appearance of multinucleated cells as well as the expression of α -actin mRNA. An *in vitro* BrdU proliferation assay, however, demonstrated that a small percentage of cells, approximately 12%, have not undergone terminal differentiation under the conditions used.

5 To further increase the safety of an encapsulation technology using established cell lines, the HSV-tk gene was inserted into the expression vector. This gene, in contrast to the mammalian thymidine kinase gene is capable of phosphorylating specific nucleotide analogues such as ganciclovir. The nucleoside monophosphate is then phosphorylated by cellular kinases and incorporated into
10 DNA, leading to inhibition of DNA synthesis and cell death. Dividing hCNTF-C₂C₁₂ cells carrying the HSV-tk gene were killed by the addition of 5 μ M ganciclovir whereas differentiated hCNTF-C₂C₁₂ cells were not affected by the treatment. It should therefore be possible to specifically eliminate the dividing C₂C₁₂ cells within the capsule before the implantation.

15 To evaluate the efficacy of our hCNTF delivery system, an *in vivo* axotomy model was used. The slow and continuous release of hCNTF from the encapsulated cells was able to enhance the survival of motoneurons following facial nerve lesion in neonatal rats. The rescue was, however, lower than the results obtained with encapsulated BHK-hCNTF cells. The lower amount of hCNTF
20 produced by the hCNTF-C₂C₁₂ clone #15 (200 ng hCNTF/10⁶ cells/day as compared) to the BHK-hCNTF cells (5 μ g hCNTF/10⁶ cells/day), may explain this difference. Recently the CNTF-C₂C₁₂ clone 3 obtained by transfecting the cells with a pNUT plasmid containing the neomycin resistance gene as a dominant selectable marker and the DHFR gene for gene amplification was shown to produce
25 approximately 2 μ g hCNTF/10⁶ cells/ day.

 The long-term survival of encapsulated C₂C₁₂ myoblasts was measured into rats. The intrathecal implantation of CNTF-releasing capsules demonstrated that C₂C₁₂ myoblasts survive in the CSF and that they produce significant amounts of hCNTF after 3 months. Taking into account the increasing
30 CNTF secretion of capsules kept *in vitro* during the same period and the histological analysis of these capsules, it appears, as expected from the BrdU

- 50 -

experiment, that not all C₂C₁₂ cells are post-mitotic. Over time, the small percentage of proliferating cells progressively fill the capsule. *In vivo*, however, such a proliferation has not been observed. This suggests that in the CSF, C₂C₁₂ cells either divide very slowly or stop growing after a few cycles. When encapsulated

5 hCNTF-BHK cells were implanted in the subarachnoid space of rats, a CNTF secretion corresponding to 5-20% of the pre-implantation value was measured at day 56, whereas an increase in CNTF production was observed at 3 months in 4 out of the 5 animals implanted with encapsulated hCNTF-C₂C₁₂ cells.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT: CytoTherapeutics, Inc.
Aebischer, Patrick
Baetge, Edward E
Hammang, Joseph P
- (ii) TITLE OF INVENTION: METHOD FOR TREATING AMYOTROPHIC LATERAL
SCLEROSIS
- (iii) NUMBER OF SEQUENCES: 2
- 10 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: FISH & NEAVE
(B) STREET: 1251 Ave. of the Americas
(C) CITY: New York
(D) STATE: New York
15 (E) COUNTRY: USA
(F) ZIP: 10020-1104
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
20 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
25 (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/537,338
(B) FILING DATE: 02-OCT-1995
- (viii) ATTORNEY/AGENT INFORMATION:
30 (A) NAME: Elrifi, Ivor R
(B) REGISTRATION NUMBER: 39,529
(C) REFERENCE/DOCKET NUMBER: CTI-33 CIP
- (ix) TELECOMMUNICATION INFORMATION:
35 (A) TELEPHONE: (212) 596-9000
(B) TELEFAX: (212) 596-9090

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9534 base pairs
(B) TYPE: nucleic acid
40 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

	GGTACCTTGG	TTTTTAAAAC	CAGCCTGGAG	TAGAGCAGAT	GGGTTAAGGT	GAGTGACCCC	60
	TCAGCCCTGG	ACATTCTTAG	ATGAGCCCCC	TCAGGAGTAG	AGAATAATGT	TGAGATGAGT	120
	TCTGTTGGCT	AAAATAATCA	AGGCTAGTCT	TTATAAAACT	GTCTCCTCTT	CTCCTAGCTT	180
5	CGATCCAGAG	AGAGACCTGG	GCGGAGCTGG	TCGCTGCTCA	GGAACTCCAG	GAAAGGAGAA	240
	GCTGAGGTTA	CCACGCTGCG	AATGGGTTTA	CGGAGATAGC	TGGCTTTCGG	GGGTGAGTTC	300
	TCGTAAACTC	CAGAGCAGCG	ATAGGCCGTA	ATATCGGGGA	AAGCACTATA	GGGACATGAT	360
	GTTCCACACG	TCACATGGGT	CGTCCTATCC	GAGCCAGTCG	TGCCAAAGGG	GCGGTCCC GC	420
	TGTGCACACT	GGCGCTCCAG	GGAGCTCTGC	ACTCCGCCCC	AAAAGTGCGC	TCGGCTCTGC	480
10	CAAGGACGCG	GGGCGCGTGA	CTATGCGTGG	GCTGGAGCAA	CCGCCTGCTG	GGTGCAAACC	540
	CTTTGCGCCC	GGACTCGTCC	AACGACTATA	AAGAGGGCAG	GCTGTCTCTT	AAGCGTCACC	600
	CCTAGAGTCG	AGCTGTGACG	GTCCTTACAA	TGAAATGCAG	CTGGGTTATC	TTCTTCCTGA	660
	TGGCAGTGGT	TACAGGTAAG	GGGCTCCCAA	GTCCCAAAC	TGAGGGTCCA	TAAACTCTGT	720
	GACAGTGGCA	ATCACTTTGC	CTTTCTTTCT	ACAGGGGTGA	ATTTCGGCTT	CACAGAGCAT	780
15	TCACCGCTGA	CCCCTCACCG	TCGGGACCTC	TGTAGCCGCT	CTATCTGGCT	AGCAAGGAAG	840
	ATTCGTTTCC	ACCTGACTGC	TCTTACGGAA	TCCTATGTAA	GTTGCCTATT	TTGCTGTTAT	900
	CTGTTTTTCCC	TTCATCTTTT	TTGATCCAGC	AACTTACCAT	CACGCATCAG	CTCCATTACC	960
	AATTGTGAAA	GCTCTAATCA	TATAGTCATT	CATATAGGTT	ATTTGACATG	GGCCCTTCCC	1020
	TTGAGGAAAC	CCATGTGACT	TTATTTTCTT	CCTCTGGGCT	GTTTAGGAGA	TGAAGTTACT	1080
20	TGAATGAGAA	AATATATATG	GAGTTC TAGA	AAGGATGGT	TTATATGTCT	TGGAGGCTAT	1140
	TCCAAATTTA	TTGGCATATA	TTCTGAATAC	TACTAGAACA	GATTAGCCAT	GGGCCCTCTG	1200
	GGTTCTTCAT	AGCCATTGTT	CTGAATTTTT	TAGCTATGTA	AATGAAAGGT	TTATGGGATA	1260
	GGAAGAGTAC	TATGAACGTG	GGAGGAATTT	GTAATCCTA	CCAATTTCTC	CTATATAGCA	1320
	TTAGCCACCC	ACCTTTTAGT	ATTCTGCATC	AAAAGTAGAT	TGTGTCTAAA	GAGAAAGGTA	1380
25	AGCTATCAAA	AGGATCTCCT	AGAAGATTCA	TTGGAAACTT	GTGGAAGTGT	CAAATTCCTG	1440
	AGCTAATTCT	GGAGTTCCAG	ATTTGTCTTC	TAACAGTAAG	GGGATCCCCA	CTAATTTCCA	1500
	CCTGAGATAT	GCTGTGGAAA	TACTCCAACC	CCTGTGGAGA	GTTTTGAATT	TAGGCTGAGA	1560
	ACTGATTTAT	CTTTGTACAG	CCTCACCAGA	CAGAAATCAG	ACTCTTTGGG	AGTGCTCAAT	1620
	GGGGAGAGGG	AAGTTAGAGA	AATTCTACAA	TGGCTATATT	CCAAGTTTTC	CTAGTTGTGG	1680
30	CCAGTGTCTT	TTACAAGTAT	GTTTAAAAAT	ACTTTAATAT	GATTAAAATA	TTCCAGTTAA	1740
	TGAGAGAGTT	TGAAGTGAGA	AGGAAAAATT	CTTCTAAATC	AGTTTTCAAC	CTTTAGAACT	1800
	CAATAAAATC	TGAACATTCT	TCTAAGAAAA	ATCCATAGGT	AGTCAATTTT	AGGCAGTATT	1860
	GGGTCTTTCT	AAAGTCCAGT	CATAGAGCCC	AAATTAAGAG	TTCCTACTGT	AGACATATTA	1920
	TTTACTTTAC	AACTGGATC	CTTGGCCAGT	GAGATGAGTG	AGATTTTGTA	TGAAATTTAG	1980
35	GGTGATTTAA	GGACACTGGG	GTGATGACAG	AAGATGTGGT	GTTTTCTCTG	ATCCTCGGCC	2040
	AGGTGAAGCA	TCAGGGCCTG	AACAAGAACA	TCAACCTGGA	CTCTGCGGAT	GGGATGCCAG	2100
	TGGCAAGCAC	TGATCAGTGG	AGTGAGCTGA	CCGAGGCAGA	GCGACTCCAA	GAGAACCTTC	2160
	AAGCTTATCG	TACCTTCCAT	GTTTTGTTGG	CCAGGCTCTT	AGAAGACCAG	CAGGTGCATT	2220
	TTACCCCAAC	CGAAGGTGAC	TTCCATCAAG	CTATACATAC	CCTTCTTCTC	CAAGTCGCTG	2280
40	CCTTTGCATA	CCAGATAGAG	GAGTTAATGA	TACTCCTGGA	ATACAAGATC	CCCCGCAATG	2340
	AGGCTGATGG	GATGCCTATT	AATGTTGGAG	ATGGTGGTCT	CTTTGAGAAG	AAGCTGTGGG	2400
	GCCTAAAGGT	GCTGCAGGAG	CTTTCACAGT	GGACAGTAAG	GTCCATCCAT	GACCTTCGTT	2460
	TCATTTCTTC	TCATCAGACT	GGGATCCCAG	CACGTGGGAG	CCATTATATT	GCTAACACA	2520
	AGAAAATGTA	GCAGTTAAGA	TCCACTAGCC	GGGTGGCATC	CCTGTGACCC	CTCCCCAGTG	2580
45	CCTCTCCTGG	CCCTGGAAGT	TGCCACTCCA	GTGCCACCA	GCCTTGTCCT	AATAAAATTA	2640
	AGTTGCATCA	TTTTGTCTGA	CTAGGTGTCC	TTCTATAATA	TTATGGGGTG	GAGGGGGGTG	2700

	GTATGGAGCA	AGGGGCAAGT	TGGGAAGACA	ACCTGTAGGG	CCTGCGGGGT	CTATTGGGAA	2760
	CCAAGCTGGA	GTGCAGTGGC	ACAATCTTGG	CTCACTGCAA	TCTCCGCCTC	CTGGGTTCAA	2820
	GCGATTCTCC	TGCCTCAGCC	TCCCGACTAG	TTCTAGAGCG	GCCGCTCTAG	AACTAGTGGA	2880
	TCCCCCGGGC	TGCAGGAATT	CGATATCAAG	CTTATCGATA	CCGTGCGACTG	CTTCATCCCC	2940
5	GTGGCCCGTT	GCTCGCGTTT	GCTGGCGGTG	TCCCCGGAAG	AAATATATTT	GCATGTCTTT	3000
	AGTTCTATGA	TGACACAAAC	CCCGCCAGC	GTCTTGTTCAT	TGGCGAATTC	GAACACGCAG	3060
	ATGCAGTCGG	GGCGGCGCGG	TCCCAGGTCC	ACTTCGCATA	TTAAGGTGAC	GCGTGTGGCC	3120
	TCGAACACCG	AGCGACCCTG	CAGCGACCCG	CTTAACAGCG	TCAACAGCGT	GCCGCAGATC	3180
	TTGGTGGCGT	GAAACTCCCC	CACCTCTTCG	GCAAGCGCCT	TGTAGAAGCG	CGTATGGCTT	3240
10	CGTACCCCTG	CCATCAACAC	GCGTCTGCGT	TCGACCAGGC	TGCGCGTTCT	CGCGGCCATA	3300
	GCAACCGACG	TACGGCGTTG	CGCCCTCGCC	GGCAGCAAGA	AGCCACGGAA	GTCCGCCTGG	3360
	AGCAGAAAAT	GCCCACGCTA	CTGCGGGTTT	ATATAGACGG	TCCTCACGGG	ATGGGGAAAA	3420
	CCACCACCAC	GCAACTGCTG	GTGGCCCTGG	GTTGCGCGA	CGATATCGTC	TACGTACCCG	3480
	AGCCGATGAC	TTACTGGCAG	GTGCTGGGGG	CTTCCGAGAC	AATCGCGAAC	ATCTACACCA	3540
15	CACAACACCG	CCTCGACCAG	GGTGAGATAT	CGGCCGGGGA	CGCGGCGGTG	GTAATGACAA	3600
	GCGCCAGAT	AACAATGGGC	ATGCCTTATG	CCGTGACCGA	CGCCGTTCTG	GTCCTCATA	3660
	TCGGGGGGGA	GGCTGGGAGC	TCACATGCCC	CGCCCCGGC	CCTCACCTC	ATCTTCGACC	3720
	GCCATCCCAT	CGCCGCCCTC	CTGTGCTACC	CGGCCACGCG	ATACCTTATG	GGCAGCATGA	3780
	CCCCCAGGC	CGTGCTGGCG	TTCGTGGCCC	TCATCCCGCC	GACCTTGCCC	GGCACAAACA	3840
20	TCGTGTTGGG	GGCCCTTCCG	GAGGACAGAC	ACATCGACCG	CCTGGCCAAA	CGCCAGCGCC	3900
	CCGGCGAGCG	GCTTGACCTG	GCTATGTTGG	CCGCGATTTCG	CCGCGTTTAC	GGGCTGCTTG	3960
	CCAATACGGT	GCGGTATCTG	CAGGGCGGCG	GGTCTGTGGC	GGAGGATTGG	GGACAGCTTT	4020
	CGGGGACGGC	CGTGCCGCCC	CAGGGTGCCG	AGCCCCAGAG	CAACGCGGGC	CCACGACCCC	4080
	ATATCGGGGA	CACGTTATTT	ACCCTGTTTC	GGGCCCCCGA	GTTGCTGGCC	CCCAACGGCG	4140
25	ACCTGTATAA	CGTGTTTGCC	TGGGCCTTGG	ACGTCTTGGC	CAAACGCCTC	CGTCCCATGC	4200
	ACGTCTTTAT	CCTGGATTAC	GACCAATCGC	CCGCCGGCTG	CCGGGACGCC	CTGCTGCAAC	4260
	TTACCTCCGG	GATGGTCCAG	ACCCACGTCA	CCACCCAGG	CTCCATACCG	ACGATCTGCG	4320
	ACCTGGCGCG	CACGTTTGCC	CGGGAGATGG	GGGAGGCTAA	CTGAAACACG	GAAGGAGACA	4380
	ATACCGGAAG	GAACCCGCGC	TATGACGGCA	ATAAAAAGAC	AGAATAAAAC	GCACGGGTGT	4440
30	TGGGTGTTTT	GTTCATAAAC	GCGGGGTTTC	GTCCCAGGGC	TGGCACTCTG	TCGATACCCC	4500
	ACCGAGACCC	CATTGGGGCC	AATACGCCCG	CGTTTCTTCC	TTTTCCCCAC	CCCAACCCCC	4560
	AAGTTCGGGT	GAAGGCCCCAG	GGCTCGCAGC	CAACGTCGGG	GCGGCAAGCC	CGCCATAGCC	4620
	ACGGGCCCCG	TGGGTTAGGG	ACGGGTCCC	CCATGGGGAA	TGGTTTATGG	TTCTGTTTTG	4680
	TTATTCTTTT	GGGCGTTGCG	TGGGGTCAGG	TCCACGACTG	GACTGAGCAG	ACAGACCCAT	4740
35	GGTTTTTGGG	TGGCCTGGGC	ATGGACCGCA	TGTACTGGCG	CGACACGAAC	ACCGGGCGTC	4800
	TGTGGCTGCC	AAACACCCCC	GACCCCCAAA	AACCACCGCG	CGGATTTCTG	GCGCCGCCGG	4860
	ACGAACTAAA	CCTGACTACG	GCATCTCTGC	CCCTTCTTCG	CTGGTACGAG	GAGCGCTTTT	4920
	GTTTTGTATT	GGTCACCACG	GCCGAGTTTC	CGCGGGACCC	CGGCCAGTCG	ACCTCGAGCG	4980
	GCCGCTAATT	CGTAATCATG	GTCATAGCTG	TTCTCTGTGT	GAAATTGTTA	TCCGCTCACA	5040
40	ATTCCACACA	ACATACGAGC	CGGAAGCATA	AAGTGTAAG	CCTGGGGTGC	CTAATGAGTG	5100
	AGCTAACTCA	CATTAATTGC	GTTGCGCTCA	CTGCCCGCTT	TCCAGTCGGG	AAACCTGTCG	5160
	TGCCAGCTGC	ATTAATGAAT	CGGCCAACGC	GCGGGGAGAG	GCGGTTTTCG	TATTGGGCGC	5220
	TCTTCCGCTT	CCTCGCTCAC	TGACTCGCTG	CGCTCGGTTCG	TTCGGCTGCG	GCGAGCGGTA	5280
	TCAGCTCACT	CAAAGGCGGT	AATACGGTTA	TCCACAGAAT	CAGGGGATAA	CGCAGGAAAG	5340
45	AACATGTGAG	CAAAGGCCA	GCAAAAGGCC	AGGAACCGTA	AAAAGGCCGC	GTTGCTGGCG	5400
	TTTTTCCATA	GGCTCCGCCC	CCCTGACGAG	CATCACAAA	ATCGACGCTC	AAGTCAGAGG	5460
	TGGCGAAACC	CGACAGGACT	ATAAAGATAC	CAGGCCTTTC	CCCCTGGAAG	CTCCCTCGTG	5520

	CGCTCTCCTG	TTCCGACCCCT	GCCGCTTACC	GGATACCTGT	CCGCCTTTCT	CCCTTCGGGA	5580
	AGCGTGGCGC	TTTCTCATAG	CTCACGCTGT	AGGTATCTCA	GTTCCGGTGTA	GGTCGTTCCG	5640
	TCCAAGCTGG	GCTGTGTGCA	CGAACCCCCC	GTTCCAGCCCG	ACCGCTGCGC	CTTATCCGGT	5700
	AACTATCGTC	TTGAGTCCAA	CCCGGTAAGA	CACGACTTAT	CGCCACTGGC	AGCAGCCACT	5760
5	GGTAACAGGA	TTAGCAGAGC	GAGGTATGTA	GGCGGTGCTA	CAGAGTTCTT	GAAGTGGTGG	5820
	CCTAACTACG	GCTACACTAG	AAGGACAGTA	TTTGGTATCT	GCGCTCTGCT	GAAGCCAGTT	5880
	ACCTTCGGAA	AAAGAGTTGG	TAGCTCTTGA	TCCGGCAAAC	AAACCACCGC	TGGTAGCGGT	5940
	GGTTTTTTTG	TTTGCAAGCA	GCAGATTACG	CGCAGAAAAA	AAGGATCTCA	AGAAGATCCT	6000
	TTGATCTTTT	CTACGGGGTC	TGACGCTCAG	TGGAACGAAA	ACTCACGTTA	AGGGATTTTG	6060
10	GTCATGAGAT	TATCAAAAAG	GATCTTCACC	TAGATCCTTT	TAAATTAATA	ATGAAGTTTT	6120
	AAATCAATCT	AAAGTATATA	TGAGTAAACT	TGGTCTGACA	GTTACCAATG	CTTAATCAGT	6180
	GAGGCACCTA	TCTCAGCGAT	CTGTCTATTT	CGTTCATCCA	TAGTTGCCTG	ACTCCCCGTC	6240
	GTGTAGATAA	CTACGATACG	GGAGGGCTTA	CCATCTGGCC	CCAGTGCTGC	AATGATACCG	6300
	CGAGACCCAC	GCTCACCGGC	TCCAGATTTA	TCAGCAATAA	ACCAGCCAGC	CGGAAGGGCC	6360
15	GAGCGCAGAA	GTGGTCCTGC	AACTTTATCC	GCCTCCATCC	AGTCTATTAA	TTGTTGCCGG	6420
	GAAGCTAGAG	TAAGTAGTTC	GCCAGTTAAT	AGTTTGCACA	ACGTTGTTGC	CATTGCTACA	6480
	GGCATCGTGG	TGTCACGCTC	GTCGTTTGGT	ATGGCTTCAT	TCAGCTCCGG	TTCCCAACGA	6540
	TCAAGGCGAG	TTACATGATC	CCCCATGTTG	TGCAAAAAG	CGTTAGCTC	CTTCGGTCCT	6600
	CCGATCGTTG	TCAGAAGTAA	GTTGGCCGCA	GTGTTATCAC	TCATGGTTAT	GGCAGCACTG	6660
20	CATAATTCTC	TTACTGTTCAT	GCCATCCGTA	AGATGCTTTT	CTGTGACTGG	TGAGTACTCA	6720
	ACCAAGTCAT	TCTGAGAATA	GTGTATGCGG	CGACCGAGTT	GCTCTTGCCC	GGCGTCAATA	6780
	CGGGATAATA	CCGCGCCACA	TAGCAGAACT	TAAAAGTGC	TCATCATTGG	AAAACGTTCT	6840
	TCGGGGCGAA	AACTCTCAAG	GATCTTACCG	CTGTTGAGAT	CCAGTTCGAT	GTAACCCACT	6900
	CGTGCACCCA	ACTGATCTTC	AGCATCTTTT	ACTTTCACCA	GCGTTTCTGG	GTGAGCAAAA	6960
25	ACAGGAAGGC	AAAATGCCGC	AAAAAAGGGA	ATAAGGGCGA	CACGGAAATG	TTGAATACTC	7020
	ATACTCTTCC	TTTTTCAATA	TTATTGAAGC	ATTTATCAGG	GTTATTGTCT	CATGAGCGGA	7080
	TACATATTTG	AATGTATTTA	GAAAAATAAA	CAAATAGGGG	TTCCGCGCAC	ATTTCCCCGA	7140
	AAAGTGCCAC	CTGACGTCTA	AGAAACCATT	ATTATCATGA	CATTAACCTA	TAAAAATAGG	7200
	CGTATCACGA	GGCCCTTTTCG	TCTCGCGCGT	TTCGGTGATG	ACGGTGAAAA	CCTCTGACAC	7260
30	ATGCAGCTCC	CGGAGACGGT	CACAGCTTGT	CTGTAAGCGG	ATGCCGGGAG	CAGACAAGCC	7320
	CGTCAGGGCG	CGTCAGCGGG	TGTTGGCGGG	TGTCGGGGCT	GGCTTAACCTA	TGCGGCATCA	7380
	GAGCAGATTG	TACTGAGAGT	GCACCATATG	CGGTGTGAAA	TACCGCACAG	ATGCGTAAGG	7440
	AGAAAATACC	GCATCAGGCG	CCATTGCGCA	TTCAGGCTGC	GCAACTGTTG	GGAAGGGCGA	7500
	TCGGTGCGGG	CCTCTTCGCT	ATTACGCCAG	CTGGCGAAAG	GGGGATGTGC	TGCAAGGCGA	7560
35	TTAAGTTGGG	TAACGCCAGG	GTTTTCCCAG	TCACGACGTT	GTAAAACGAC	GGCCAGTGCC	7620
	AAGCTTGCAT	GCCTGCAGGT	CGACGCTCTC	CCTTATGCGA	CTCCTGCATT	AGGAAGCAGC	7680
	CCAGTAGTAG	GTTGAGGCCG	TTGAGCACCG	CCGCCGCAAG	GAATGGTGCA	TGCAAGGAGA	7740
	TGGCGCCCAA	CAGTCCCCCG	GCCACGGGGC	CTGCCACCAT	ACCCACGCCG	AAACAAGCGC	7800
	TCATGAGCCC	GAAGTGGCGA	GCCCCATCTT	CCCCATCGGT	GATGTCGGCG	ATATAGGCGC	7860
40	CAGCAACCGC	ACCTGTGGCG	CCGGTGATGC	CGGCCACGAT	GCGTCCGGCG	TAGAGGATCT	7920
	CTGACGGAAG	GAAAGAAGTC	AGAAGGCAAA	AACGAGAGTA	ACTCCACAGT	AGCTCCAAAT	7980
	TCTTTATAAG	GGTCAATGTC	CATGCCCCAA	AGCCACCCAA	GGCACAGCTT	GGAGGCTTGA	8040
	ACAGTGGGAC	ATGAACAAGA	GATGATTAGG	CAGAGGTGAA	AAAGTTGCAT	GGTGTGGTGG	8100
	CGCAGACCAA	TTTATGCCTA	CAGCCTCCTA	ATACAAAGAC	CTTTAACCTA	ATCTCCTCCC	8160
45	CCAGCTCCTC	CCAGTCCTTA	AACACACAGT	CTTTGAAGTA	GGCCTCAAGG	TCGGTCTGTTG	8220
	ACATTGCTGG	GAGTCCAAGA	GTCCTCTTAT	GTAAGACCTT	GGCAGGATC	TGATGGGCGT	8280
	TCACGGTGGT	CTCCATGCAA	CGTGCAGAGG	TGAAGCGAAG	TGCACACGGA	CCGGCAGATG	8340

	AGAAGGCACA	GACGGGGAGA	CCGCGTAAAG	AGAGGTGCGC	CCCGTGGTCG	GCTGGAACGG	8400
	CAGACGGAGA	AGGGGACGAG	AGAGTCCCAA	GCGGCCCGC	GAGGGGTCGT	CCGCGGGATT	8460
	CAGCGCCGAC	GGGACGTAAA	CAAAGGACGT	CCCGCGAAGG	ATCTAAAGCC	AGCAAAAGTC	8520
	CCATGGTCTT	ATAAAAATGC	ATAGCTTTAG	GAGGGGAGCA	GAGAACTTGA	AAGCATCTTC	8580
5	CTGTTAGTCT	TTCTTCTCGT	AGACTTCAA	CTTATACTTG	ATGCCTTTTT	CCTCCTGGAC	8640
	CTCAGAGAGG	ACGCCTGGGT	ATTCTGGGAG	AAGTTTATAT	TTCCCAAAT	CAATTTCTGG	8700
	GAAAAACGTG	TCACTTTCAA	ATTCTTGCAT	GATCCTTGTC	ACAAAGAGTC	TGAGGTGGCC	8760
	TGGTTGATTC	ATGGCTTCT	GGTAAACAGA	ACTGCCTCCG	ACTATCCAAA	CCATGTCTAC	8820
	TTTACTTGCC	AATTCCGGTT	GTTCAATAAG	TCTTAAGGCA	TCATCCAAAC	TTTTGGCAAG	8880
10	AAAATGAGCT	CCTCGTGGTG	GTTCTTTGAG	TTCTCTACTG	AGAACTATAT	TAATTCTGTC	8940
	CTTTAAAGGT	CGATTCTTCT	CAGGAATGGA	GAACCAGGTT	TTCCTACCCA	TAATCACCAG	9000
	ATTCTGTTTA	CCTTCCACTG	AAGAGGTTGT	GGTCATTCTT	TGGAAGTACT	TGAACTCGTT	9060
	CCTGAGCGGA	GGCCAGGGTA	GGTCTCCGTT	CTTGCCAATC	CCCATATTTT	GGGACACGGC	9120
	GACGATGCAG	TTCAATGGTC	GAACCATGAT	GGCAATTCTA	GAATCGATAA	GCTTTTTGCA	9180
15	AAAGCCTAGG	CCTCCAAAAA	AGCCTCCTCA	CTACTTCTGG	AATAGCTCAG	AGGCCGAGGC	9240
	GGCCTCGGCC	TCTGCATAAA	TAAAAAAAAT	TAGTCAGCCA	TGGGGCGGAG	AATGGGCGGA	9300
	ACTGGGCGGA	GTTAGGGGCG	GGATGGGCGG	AGTTAGGGGC	GGGACTATGG	TTGCTGACTA	9360
	ATTGAGATGC	ATGCTTTGCA	TACTTCTGCC	TGCTGGGGAG	CCTGGGGACT	TTCCACACCT	9420
	GGTTGCTGAC	TAATTGAGAT	GCATGCTTTG	CATACTCTG	CCTGCTGGGG	AGCCTGGGGA	9480
20	CTTTCCACAC	CCTAACTGAC	ACACATTCCA	CAGCTGGTTC	TTCCGCCTC	AGAA	9534

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Asn Ser Ala Phe Thr Glu His Ser

1

5

- 56 -

WE CLAIM:

1. A method for treating amyotrophic lateral sclerosis in a patient suffering therefrom comprising administering, directly into the central nervous system of said patient, ciliary neurotrophic factor, or active fragment, mutein, or modified variant thereof, in a dose sufficient to maintain a measurable level of ciliary neurotrophic factor protein, or active fragment, mutein, or modified variant thereof, up to 1000 ng/ml in the cerebrospinal fluid.
2. The method of claim 1 wherein the level in the cerebrospinal fluid is between 0.1 and 100 ng/ml.
3. The method of claim 1 wherein administration is into the intrathecal space.
4. The method of claim 1 wherein administration is into the ventricular space.
5. The method of claim 1 wherein the ciliary neurotrophic factor is full-length human ciliary neurotrophic factor.
6. The method of claim 1 wherein the ciliary neurotrophic factor, or active fragment, mutein, or modified variant thereof, is delivered from an implanted biocompatible capsule containing ciliary neurotrophic factor-secreting cells.
7. The method of claim 6 wherein the capsule is immunoisolatory.
8. The method of claim 6 wherein the capsule is implanted in the intrathecal space.

9. The method of claim 1 wherein a second molecule is co-delivered to the patient, the second molecule selected from the group consisting of BDNF, GDNF, NT-3, NT-4/5, NT-6, CT-1, IFN- β , IFN- α , and mixtures thereof.

10. A method for treating amyotrophic lateral sclerosis in a patient suffering therefrom comprising the administration of a dose between about 1 to 10,000 ng/24 hours of ciliary neurotrophic factor protein, or active fragment, mutein, or modified variant thereof, directly into the central nervous system, such dose being sufficient to produce a measurable level of ciliary neurotrophic factor, or active fragment, mutein, or modified variant thereof in the cerebrospinal fluid.

11. The method of claim 10 wherein the dose is between 250 to 1000 ng/24 hours.

12. The method of claim 10 wherein administration is into the intrathecal space.


13. The method of claim 10 wherein administration is into the ventricular space.

14. The method of claim 10 wherein the ciliary neurotrophic factor is full-length human ciliary neurotrophic factor.

15. The method of claim 10 wherein the ciliary neurotrophic factor, or active fragment, mutein, or modified variant thereof is delivered from an implanted biocompatible capsule containing ciliary neurotrophic factor-secreting cells.

16. The method of claim 15 wherein the capsule is immunoisolatory.

17. The method of claim 15 wherein the capsule is implanted in the intrathecal space.
18. The method of claim 10 wherein a second molecule is co-delivered to the patient, the second molecule selected from the group consisting of BDNF, GDNF, NT-3, NT-4/5, NT-6, CT-1, IFN- β , IFN- α , and mixtures thereof.
19. A system for treating amyotrophic lateral sclerosis in a patient suffering therefrom comprising at least one biocompatible device, each device comprising:
- a core of living cells, said cells secreting ciliary neurotrophic factor, or active fragment, mutein, or modified variant thereof;
 - a jacket surrounding the core, the jacket comprising a biocompatible material; the system providing a measurable level of ciliary neurotrophic factor protein, or active fragment, mutein, or modified variant thereof, up to 1000 ng/ml when implanted in the cerebrospinal fluid of the patient.
20. The system of claim 19 wherein the level of in the cerebrospinal fluid is between 0.1 and 100 ng/ml.
21. The system of claim 19 wherein the jacket material is a hydrogel or a thermoplastic.
22. The system of claim 19 wherein the system comprises between one and ten devices.



2 / 10

FIG. 2a







FIG. 2b



3/10



4/10





FIG.5a






FIG.5b





7 / 10

FIG. 7a




FIG. 7b




FIG. 7c




FIG. 7d





FIG. 7e






FIG. 8

10/ 10




FIG. 9

INTERNATIONAL SEARCH REPORT

national Application No
PCT/US 96/15824

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K48/00 A61K38/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EUROPEAN NEUROLOGY, vol. 35, March 1995, pages 65-68, XP000615583 AEBISCHER P. ET AL: "Treatment of Amyotrophic lateral sclerosis using a gene therapy approach" see the whole document ---	1-22
X	EXPERIENTIA, vol. 51, February 1995, page a83 XP002022377 DEGLON N. ET AL: "Genetically engineered polymer-encapsulated cells as a new strategy for the treatment of als" see abstract S17-19 --- -/--	1-22

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>
--	--

Date of the actual completion of the international search <p style="text-align: center;">9 January 1997</p>	Date of mailing of the international search report <p style="text-align: center;">3 1. 01. 97</p>
--	--

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Authorized officer <p style="text-align: center;">Fernandez y Branas, F</p>
---	--

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 96/15824

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 7, June 1995, pages 1313-1322, XP000615598 SAGOT Y. ET AL: "Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse" see the whole document ---</p>	1-22
X	<p>WO,A,95 05452 (CYTOTHERAPEUTICS INC ;BAETGE E EDWARD (US); HAMMANG JOSEPH P (US);) 23 February 1995 see claims 18-21 see page 31, line 31 - page 32, line 2 see page 21, line 3 - page 25, line 7 see page 79, line 12 - line 14 ---</p>	1-22
X	<p>WO,A,92 19195 (UNIV BROWN RES FOUND) 12 November 1992 see claims 12,15,16,49,57 see page 31, line 14 - line 33 see page 42, line 1 - line 20 ---</p>	19-22
A	<p>WO,A,95 22560 (SYNTEX SYNERGEN NEUROSCIENCE J) 24 August 1995 see the whole document ---</p>	1-22
A	<p>WO,A,94 17818 (SYNTEX SYNERGEN NEUROSCIENCE J) 18 August 1994 see the whole document ---</p>	1-22
A	<p>WO,A,94 09134 (REGENERON PHARMA) 28 April 1994 see the whole document -----</p>	1-22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 15824

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-18
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/15824

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9505452	23-02-95	AU-A- 7568094	14-03-95
		CA-A- 2169292	23-02-95
		FI-A- 960611	09-04-96
		NO-A- 960547	12-04-96

WO-A-9219195	12-11-92	AU-B- 666118	01-02-96
		AU-A- 2004192	21-12-92
		AU-A- 3902095	01-02-96
		EP-A- 0585368	09-03-94
		JP-T- 6507412	25-08-94
		NO-A- 933842	25-10-93

WO-A-9522560	24-08-95	AU-A- 1847695	04-09-95

WO-A-9417818	18-08-94	AU-A- 6169894	29-08-94
		CA-A- 2155540	18-08-94
		EP-A- 0682525	22-11-95

WO-A-9409134	28-04-94	US-A- 5349056	20-09-94
		AU-B- 667996	18-04-96
		AU-A- 5326094	09-05-94
		EP-A- 0666912	16-08-95
		JP-T- 7506005	06-07-95
		ZA-A- 9307482	26-04-94
